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Inherited endocrine tumors have been increasingly recognized in clinical practice, although some difficulties
still exist in differentiating these conditions from their sporadic endocrine tumor counterparts. Here, we list the
12 main topics that could add helpful information and clues for performing an early differential diagnosis to
distinguish between these conditions. The early diagnosis of patients with inherited endocrine tumors may be
performed either clinically or by mutation analysis in at-risk individuals. Early detection usually has a large
impact in tumor management, allowing preventive clinical or surgical therapy in most cases. Advice for the
clinical and surgical management of inherited endocrine tumors is also discussed. In addition, recent clinical
and genetic advances for 17 different forms of inherited endocrine tumors are briefly reviewed.
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& INTRODUCTION
Familial endocrine tumors have been of interest for many
years (1). This subject likely attracted attention from
researchers and clinicians because patients with inherited
endocrine tumors (IETs) usually present rare tumor types,
genealogies with several affected family members and
strikingly common clinical and genetic features. The first
report of pheochromocytoma (PHEO) was presented by
Felix Frankel in 1888 and described a patient who had
recently been characterized as having multiple endocrine
neoplasia (MEN) type 2 (MEN2) (2). A familial predisposi-
tion to endocrine tumors was described in 1940, although
the multiple endocrine adenoma entity was recognized a
decade later by Wermer (3,4). More recently, updates on
MENs have become available and recommend adequate
procedures for the management of IET patients (5-10).
However, IETs will likely remain a challenging subject of
study involving topics such as the genetic diagnosis of
asymptomatic cases, familial screening, detailed character-
ization of the phenotype, exome and transcriptome studies,
preventive surgery, new therapeutic strategies, genetic
counseling, and ethics (11,12). In addition, advanced
techniques such as sophisticated in vitro functional studies,
RNAi analysis, genomic micro- and macroarray assays,
genome-wide association studies, exome analysis, copy
number variations, whole genome sequencing, and in silico
analysis may be available on a routine and personal basis in
the near future (13). Therefore, genomics may have a long-
standing impact on the clinical and surgical management of
patients with IETs.
Despite substantial advances in the study of IETs, some
difficulties still remain, specifically in the early recognition
of IET conditions and in its differentiation from sporadic
endocrine tumors (SETs) (Table 1). The distinction between
both conditions is critical for decision making with respect
to the affected index-case and their mutation-positive family
members. Therefore, we will focus on the 12 typical clinical
and genetic characteristics of IETs that may help clinicians
to recognize IETs early and recommend preventive or early
therapeutic interventions in this review. The IET character-
istics mentioned below are intended to provide a practical
clinical approach for the care of these patients.
1 – Age at diagnosis - IETs typically tend to develop in
younger patients than their SET counterparts. Parathyroid
hyperplasia/adenomas leading to primary hyperparathyr-
oidism (HPT) associated with MEN type 1 (MEN1) are
usually diagnosed by 20-35 years of age. In contrast,
sporadic primary HPT is mostly recognized in patients
older than 50 years of age (5,14-16). Medullary thyroid
carcinoma (MTC) associated with MEN2 can be diagnosed
at early ages (,5-10 yr old), mostly in family members who
have been genetically screened for RET proto-oncogene
mutations (17-19). In addition, the highly aggressive MTC
associated with MEN2B caused by RET 918 codon muta-
tions usually develop during the first year of life (20).
Conversely, cases with sporadic MTC are usually diagnosed
at later ages (.20-30 yr old) (21). Patients with inherited
PHEO/paraganglioma who carry germline mutations in the
SDHA, SDHB, SDHC, SDHD, RET, and MAX genes are
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usually diagnosed at 20-30 years (22,23). Conversely,
sporadic PHEOs are frequently diagnosed in the fifth
decade of life (20). One exception for PHEO is found in
cases with isolated familial PHEO caused by germline
TMEM127 mutations and neurofibromatosis type 1 (NF1)-
associated PHEO, which are usually diagnosed at 40-44
years (24,25). Pituitary tumors (PITs) associated with MEN1
syndrome, Carney syndrome (CS), and familial isolated
pituitary adenoma (FIPA) are usually diagnosed in the
second decade of life, although they may occur as early as 5
years of age (8,26). These data strongly contrast with
sporadic PITs, which are usually diagnosed during the
third and fourth decades. In addition, gigantism from excess
growth hormone secretion is far more frequent in patients
with FIPA and CS than in patients with sporadic somato-
tropinomas (8,26,27). A general trend for diagnosis at early
ages is also applied to several other types of IETs. In brief,
IET cases harboring either germline-activating mutations in
proto-oncogenes or inactivating mutations in tumor sup-
pressor genes have a marked predisposition to develop
tumors at early ages.
2 – Associated tumors - Many IETs are associated with
syndromes in concert with several independent, primary
tumors in a single patient, such as a patient with MEN1 and
MEN2, von Hippel-Lindau (VHL), NF1, CS, or Li-Fraumeni
complex (LFS) (5,27). As many as 20 different endocrine and
non-endocrine tumors have been described in association
with MEN1 syndrome, such as HPT, PITs, pancreatic-
endocrine tumors (PETs), adrenal tumors, and skin neopla-
sias (5). Patients with VHL may have renal, cerebellar, and
pancreatic tumors and PHEO (28). In patients with MEN2,
MTC is found in almost all cases, whereas PHEO and HPT
are also highly prevalent (17-19,20,22). Patients with CS
usually present PITs leading to acromegaly/gigantism and
primary pigmented nodular adrenocortical disease leading
to Cushing’s syndrome (29). In patients with LFS, the
adrenocortical carcinoma (ACC) is frequently associated
with breast and ovary neoplasias. Patients with more than
one primary endocrine tumor are potential candidates for
an IET and should be actively investigated for other primary
neoplasias.
3 – Germline mutation and inheritance - The signature of
inherited tumors is the presence of a germline mutation in
the pertinent disease-causing gene. For instance, the
presence of a RET germline mutation in cases with MTC,
PHEO, or HPT define these tumors as having inherited
transmission. The finding of an NF1 germline mutation
confirms NF1 disease. A MEN1 germline mutation helps to
confirm the diagnosis of MEN1 syndrome and establish that
the condition is inherited. The same pattern occurs with
other cancer genes, although cases with either de novo
mutations or large gene deletions are exceptions to this
general rule. Conversely, the absence of a germline tumor-
causing mutation supports the diagnosis that the patient has
a SET that is frequently a counterpart of the IET.
Almost all IETs are inherited by autosomal dominant
transmission, which means that the patient’s first-degree
relatives have a 50% risk of carrying the mutated gene;
consequently, they have inherited a predisposition to
develop the specific tumor condition. Additionally, cases
with an apparently SET may harbor a germline mutation, as
is true of 1-7% of cases with sporadic MTC harboring a RET
germline mutation (8,21). Therefore, apparently sporadic
PHEOs should be analyzed for VHL, RET, and SDHx
germline mutations (30). In sum, one should consider the
pros and cons of genetic testing in apparently SET cases to
rule out a possible ‘‘hidden’’ germline mutation and avoid
missing an IET diagnosis (8,9,21).
4 – Sex ratio- Because IETs are inherited by autosomal
dominant transmission, their sex ratio is mostly 1:1,
although this value may vary within small genealogies. In
contrast, the sex ratio is 1:3 for sporadic primary HPT
caused by parathyroid adenoma, with a definite predomi-
nance of middle-aged females (5).
5 – Multicentric tumors - A typical observation in IETs is
the occurrence of multicentric tumors, as observed in
MEN2-related tumors (MTC, HPT, PHEO), MEN1-related
tumors (PETs, HPT), VHL-related PHEO, and CS (5,15,16).
Conversely, sporadic MTC, PHEO, HPT, PETs, and PITs are
usually represented by a single tumor (31,32). Sporadic
gastrinomas in particular are usually represented by a single
duodenal or pancreatic tumor, whereas multiple duodenal
gastrinomas are routinely documented in MEN1 patients
(33-35). Thus, the pre-surgical diagnosis of the IET condi-
tions is an important requirement for providing surgeons
with proper data to plan a surgical approach. For instance, a
partial pancreatectomy is usually advised in sporadic PETs
to remove a single tumor, whereas the multiple tumors
found in inherited PETs should be approached using a sub-
total or even total pancreatectomy (8,33-35).
6 – Bilateral tumors - Patients with IETs have a high risk
(up to 60%) of contralateral tumors, as verified in patients
with PHEO-associated MEN2 or VHL or in isolated familial
PHEOs caused by TMEM127, MAX, and SDHx mutations
(8,17,23-25). In addition, primary pigmented nodular adre-
nocortical disease in CS is usually bilateral, but it is
unilateral in its sporadic form (36,37). Furthermore, both
thyroid lobes are affected in MTC/MEN2, and both adrenal
glands are frequently affected in VHL and CS. Additionally,
renal cell carcinoma in VHL is frequently bilateral, although
contralateral tumors may not occur simultaneously. In
addition, the development of bilateral tumors in patients
with IETs is frequently nonsynchronous (8,17,22,38).
Conversely, most sporadic PHEO and MTC occur unilat-
erally. Thus, a long-standing clinical follow-up should be
Table 1 - Main characteristics of inherited endocrine
tumors and their sporadic endocrine tumor counterparts,
and the differential management of these conditions.
IETs SETs counterparts
Age at diagnosis low high
Associated tumors + -
Germline mutation + -
Inheritance A.D. -
Multicentric tumors + -
Bilateral tumors + -/rare
Pre-malignant stage + -
Aggressiveness . ,
Specific tumor locations + +
Mixed tumors types + -/rare
Genetic heterogeneity + -
Clinical heterogeneity + -
Founder effect + -
Two-hit model of tumorigenesis + -
Early genetic diagnosis + -
Genetic counseling + -
Pre-symptomatic diagnosis + -
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performed in IET patients to detect possible contralateral
tumors.
7 - Pre-malignant stage - IETs frequently present a pre-
neoplastic stage, as represented by a hyperplastic phase that
precedes neoplasia. One typical example is C-cell hyper-
plasia in MEN2 that evolves to MTC and is frequently
associated with increased levels of serum calcitonin (17,39).
Notably, patients who are submitted to preventive total
thyroidectomy (TTx) during this early, pre-malignant stage
and present repeatedly undetectable values of calcitonin
after 5-10 years of post-surgical follow-up can be considered
biochemically cured (40). In addition, cases of PHEO/
MEN2A and VHL-associated PHEOs present adrenomedul-
lary hyperplasia that precedes the tumor.
8 – Aggressiveness - IETs have a marked tendency to be
more aggressive than their SET counterparts. Accordingly,
FIPA-associated PITs develop faster than sporadic PITs, and
most are invasive macroadenomas at diagnosis (41,42).
Furthermore, the PITs in MEN1 are far more aggressive
than their sporadic counterparts (43). Additionally, early
occurring MEN1-associated HPTs lead to early, severe bone
and renal complications, whereas sporadic HPT usually has
a milder presentation (44-46). Cervical lymph node metas-
tases have been described before the age of 3 years in
MEN2-related MTC patients with RET codon 918 mutations.
In addition, in cases with a RET codon 634 mutation, a
micro-MTC was reported in a 2-year-old child, and local
cervical metastases were present in another 5-year-old child
(46-47). Tumor aggressiveness may be associated with
therapy resistance, as observed in MTC patients with RET
codon 804 mutations that are resistant to therapy with
tyrosine kinase inhibitors, whereas the high aggressiveness
observed in IETs is less frequently observed in SETs (48).
These data reinforce the need to perform early diagnosis in
IET patients as a crucial tool in preventive surgical therapy
or at least early treatment (48).
9 – Tumor location- IETs and their SET counterparts may
occur in different locations. Sporadic gastrinomas are
mostly located in the pancreas, whereas MEN1-related
gastrinomas are mainly located in the duodenum (8,10,33-
35). Furthermore, sporadic gastrinomas are usually repre-
sented by a single pancreatic tumor, whereas multiple
primary pancreato-duodenal gastrinomas are routinely
documented in .80% of MEN1 patients (33). The parathyr-
oid adenoma of sporadic primary HPT is mostly located in a
single gland, whereas in HPT/MEN1, all parathyroid
glands are usually affected, and there is a high risk of
developing HPT in the supernumerary and ectopic para-
thyroid glands (5,49).
These data are crucial for the surgeons who are planning
the appropriate surgical approach for IET cases. The first
surgical option for sporadic HPT is to remove the single
parathyroid adenoma (adenomectomy), whereas total para-
thyroidectomy (PTx) followed by a parathyroid implant in
the forearm or sub-total PTx is used for HPT/MEN1 cases
(49-52). In addition, sporadic insulinoma is frequently
treated with surgery by single pancreatic nodule removal,
whereas cases with insulinoma/MEN1 are usually sub-
mitted to sub-total pancreatectomy (83,117). For gastrinoma
in MEN1, subtotal or total duodenopancreatectomy or
subtotal pancreatectomy associated with duodenotomy is
applied, and partial pancreatectomy is usually the surgical
choice in sporadic gastrinoma (33,34,51,52).
10 – Mixed tumor types - Mixed tumor types occurring in
a single endocrine gland are frequent in IETs and rare in
their SET counterparts. Different types of secretory PITs
associated with either MEN1 or FIPA have been simulta-
neously reported in the same patient and in a single family.
Thus, mixed tumors secreting GH and prolactin are
frequently found in FIPA and MEN1 (8,15). In contrast,
sporadic PITs are less frequently mixed (53). Furthermore,
different secretory cell tumors may occur in PETs/MEN1,
mainly with gastrin and insulin (8,10).
11 – Genetic heterogeneity - Similar clinical features
observed in IET patients may be caused by different genes.
As an example, germline CDKN1B/p27 mutations have
been reported in MEN1-like patients who present no
germline MEN1, and this condition is called MEN4,
whereas the rat equivalent disease is named MENX (54).
In addition, inherited PHEO/paragangliomas may occur in
the context of MEN2, VHL, and isolated familial PHEO. In
these cases, several mutations may be present in genes such
as SDHA, SDHB, SDHC, SDHD, RET, VHL, TMEM127, and
MAX (23-25). In addition, approximately 80% of CS cases
are caused by a PRKAR1A mutation at chromosome 17,
although a second putative gene in chromosome 2p was
reported though not fully characterized to date (55). Patients
with the two genetic origins present similar phenotypes
(10).
Thus, for IET cases with superimposed phenotypes that
could be related to different genes, rational approaches
should be applied in genetic testing, as performed in recent
cases with isolated familial PHEO/paraganglioma (56).
12 – Clinical heterogeneity - IET patients harboring the
same specific type of germline mutation and belonging to a
single family may present a high degree of clinical
variability, as typically occurs in MEN1 (57,58). MEN1
patients may present up to 20 different tumor types, and no
consistent genotype-phenotype correlation has been
reported so far (5). Concordantly, in a very large MEN1
family (.20 affected cases) of Italian origin, we observed a
high prevalence of PITs and PETs, but no genuine genotype-
phenotype correlation (44,45). This challenging finding may
be caused by tissue-specific modulating factors, such as
epigenetic events (hypermethylation), a second MEN1
mutation, RNAi or even mutations in another gene.
Although there is a high rate of genotype-phenotype
correlation in conditions like MEN2 and VHL, a large range
of clinical heterogeneity may still be observed (20,22,30,59).
Thus, depending on the specific IET, substantial phenotypic
diversity and variable penetrance may be observed in
patients harboring the same type of mutation. Overall, a
periodic screening should be performed for all tumor types
that are potentially involved in IETs to try to provide early
diagnosis. Alternatively, genetic testing can exclude germ-
line mutations, avoiding long-standing periodic screening in
the latter cases.
Some additional comments on IETs are needed.
1 – Founder effect - Familial cancer clustering has been
one of the main avenues toward improving cancer etiology
and is an indicator of heritable gene involvement (60). A
founding VHL mutation was reported in a large conglom-
erate of PHEO patients living in the Black Forest of
Germany (30). In addition, founding mutations have been
reported in six very large MEN1 families (.20 affected
cases) (44). One of these families originally came from
Veneto, Italy to Brazil in 1889. More than 50 affected family
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members currently harbor the same specific MEN1 muta-
tion in exon 2 and are living in Sa˜o Paulo State, Brazil
(44,45). Moreover, we identified a large MEN2 familial
cluster from the northeast area of Brazil, including more
than 45 affected MEN2 cases carrying a RET Cys620Arg
mutation (20,40,61). In Germany, MEN2 families could be
traced back to the early 20th century, and a few of them have
been traced to the 19th century (62). In addition, a common
founding arg337-to-his (R337H) P53 germline mutation in
exon 10 was reported in cases with LFS from southern Brazil
(63). Recently, a high penetrance founding mutation was
reported in 287 affected cases from Trentino, Italy with
paraganglioma associated with a low prevalence of PHEO.
A common ancestor was identified from the 14th-15th
centuries (64). Additionally, a large FIPA genealogy from
northern Finland could be traced back to the 18th century
(41). Similarly, a founding couple could be traced in a FIPA
family from Ireland to the 18th century (65). In summary,
very large IET genealogies frequently carry a founding
mutation and constitute an excellent opportunity to expand
our knowledge of inherited cancer conditions. Further
topics for investigating familial cancer clustering are intra-
familial phenotype variations, possible superimposing con-
sanguineous marriages, and the occurrence of homozygous
mutations.
2 – Two-hit model of tumorigenesis - As mentioned, most
IET conditions are caused by tumor suppressor genes such
as VHL, p27, MEN1, PRKAR1A, SDHs, and TMEM127, and
the two-hit model mutation proposed by Alfred Knudson
has been appropriately applied to these conditions. This
model is based on the presence of two sequential mutations.
The first is a germline mutation inherited from a parent; by
itself, it is not sufficient to start tumor development,
although it leads to IET genetic predisposition. The second
event is a somatic mutation that occurs at random in the
same gene, within a specific tissue (endocrine gland). This
latter event results in biallelic gene inactivation and a loss of
heterozygosity (LOH) that will lead to the onset of tumor
development (66). Conversely, there are rare reports that
suggest that LOH in tumors is caused by proto-oncogenes,
although these data require validation (67). Thus, the
presence of LOH in a tumor supports the possibility that
it is inherited, most likely through tumor suppressor genes.
Management
Similar genetic and clinical approaches are frequently
applied to the management of most IETs.
1 - Pre-symptomatic diagnosis may be performed in IETs,
leading to a recommendation of preventive surgical treat-
ment for specific cases (8,9). Conversely, pre-symptomatic
diagnosis and preventive treatment is not applied to the SET
counterparts. After screening at-risk family members from
the index-case, mutation-positive carriers should be invited
for an interview at the hospital. In cases such as RET
mutation-positive carriers, preventive TTx should then be
recommended, as internationally established (8,9,62,68).
RET mutation carriers should be submitted to preventive
TTx during the first year of age (cases with RET mutations
in codons 883 or 918), by the age of 3 years (codon 634), 5
years (codons 620, 618, 609, and others) or 5-10 years (codon
804 and others) (8,9,17,62). Concordantly, we successfully
performed preventive TTx in 15 young cases in a single
extended 620-codon mutation-positive MEN2 family
(20,40,61). Some of these cases have been followed for up
to 10 years, and their calcitonin levels have remained
undetectable, indicating that a ‘‘biochemical cure’’ was
achieved (20,40,61). Preventive TTx has been successfully
performed in MEN2 children from several Latin American
countries, including Argentina, Chile, and Brazil (69-71).
Preventive subtotal or total thymectomy should be per-
formed in all MEN1 cases during PTx as recommended for
HPT/MEN1 because the thymic carcinoid is a fast-evolving
malignant tumor that is a frequent cause of death in MEN1
cases (8,10). Thus, preventive surgery may have a relevant
and impressive impact in the management and outcome of
many forms of IETs, as typically documented in MEN2-
associated MTC.
2 – Curative surgery may still be achieved in some older
IET cases in which preventive surgery is not applicable, but
relatively early diagnosis could still be performed. For
instance, curative TTx has been successfully performed at
the early developmental stages of MTC in patients up to 12
years of age, who belonged to a MEN2 family with a RET
Cys620Arg mutation (61). Similarly, MEN2A cases need to
be searched annually for PHEO, and a curative adrenalect-
omy is usually considered as soon as the adrenal tumor is
detected by CT or MRI, if the patients are symptomatic (8).
Most patients with HPT/MEN1 will benefit from PTx
performed as soon as there is a consensual indication for
surgery, including the presence of osteoporosis, renal
calculi, hypercalcemia, and an age below 50 years
(46,103,104,111,115,116,149-154). Notably, a short-term bone
mineral density improvement after total PTx followed by
parathyroid auto-transplant in the forearm has been verified
in our MEN1 cases (49,50). Interestingly, the impact of
MEN1 mutations in the management of MEN1 cases was
initially considered to be low (31). However, accumulating
data presently indicate that the early genetic diagnosis of
MEN1 germline mutations may have a substantial impact
on the clinical and surgical management of MEN1 patients.
For instance, preventive thymectomy and PTx in young,
select MEN1-associated HPT cases may prevent the devel-
opment of highly malignant thymic carcinoids and second-
ary complications of HPT, such as osteoporosis and renal
calculi (10,15). Additionally, non-functioning PETs (NF-
PETs) associated with MEN1 may occur at ages as early as
10, and adequate early surgical intervention should be
considered in these cases (10). Furthermore, early detection
and therapy in cases with GH-secreting tumor in patients
with MEN1, FIPA, and CS may prevent the development of
gigantism and further PIT expansion (8,29,37).
Taken together, these examples illustrate that early
diagnosis and treatment in IET patients have strong clinical
impacts and may ultimately lead to a better quality of life
and decrease morbidity and mortality (15,72). To achieve
these two beneficial goals, the genetic mutation analysis and
the clinical periodic screening in affected index-cases and at-
risk family members from IET genealogies should begin at
early ages (8-10).
3 - Genetic counseling should be offered to IET cases and
their at-risk relatives and may provide crucial information
for couples, although a psychological burden must be
avoided (11). Individuals who are at risk for developing
hereditary cancers should be offered surveillance to
improve their prognosis. Advisers should consider several
options, with respect to psychological distress and the
quality of life in individuals who are under surveillance for
hereditary cancers. Notably, high-risk individuals with an
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inherited predisposition for multiple tumors may be
associated with increased distress and a lower quality of
life. Common factors associated with poor psychological
outcomes include a personal history of cancer, female
gender, a first degree relative with cancer, negative illness
perceptions, and coping style. The use of a simple screening
tool to identify distressed individuals is recommended (73).
Several types of IETs have been increasingly recognized
by clinical and genetic means over recent decades. Here, we
briefly summarize the main IETs and some recent topics
and issues related to these conditions.
von Hippel-Lindau syndrome
VHL disease is a complex inherited condition caused by
germline mutations in the VHL tumor suppressor gene
located on chromosome 3p. More than 300 VHL genealogies
with VHL mutations and double VHL mutations have been
reported (http://www.umd.be/VHL/W_VHL; 74). VHL is
a rare autosomal dominant syndrome (1/36,000 live births)
with high penetrance that predisposes a patient to the
development of a panel of highly vascularized benign and
malignant tumors, such as angiomas and hemangioblasto-
mas, particularly in areas that are rich in blood vessels such
as the retina, cerebellum, and spine. Renal cell carcinoma
(RCC), PHEO, PETs (,10%), and visceral cysts (renal,
pancreatic, and epididymal) are also prevalent (75). VHL is
classified as type 1 (without PHEO), type 2A (with PHEO),
2B (PHEO and RCC), and 2C (isolated PHEO, without
hemangioblastoma or RCC). PHEO in VHL is usually
diagnosed by 30 years of age, the risk of malignancy is
5%, and it secretes high levels of normetanephrine
(.112 pg/mL). Young PHEO patients are frequently asso-
ciated with either VHL or MEN2A and less often with
MEN2B, NF1, and paraganglioma (SDH-B), sustained
hypertension with infrequent hypertensive peaks, bilateral
tumors, and malignancy (76). Classic and non-classic VHL
phenotypes have been reportedly associated with VHL
mutations. The vast majority of PETs in VHL are malignant
NF-PETs located in the pancreas. PETs in VHL are relatively
frequent (10-17%). Most are non-functioning, asymptomatic,
single pancreatic tumors; they are malignant in up to 50% of
cases and metastasize in up to 27% of cases. Further, they
are the third highest cause of death in relation to VHL (77).
Therefore, these tumors must be routinely scrutinized
during follow-ups. Head and neck paragangliomas
(HNPs) may be found in patients with VHL (78). HNPs
can occur in the sporadic or familial form, and the latter is
mostly associated with germline mutations in SDHB, SDHC,
or SDHD (SDHx). Non-SDHx HNP might occur in patients
with VHL, MEN2, and NF1. Therefore, molecular genetic
testing for VHL or RET mutations in HNP patients should
be recommended if personal and/or family history shows
evidence for one of these syndromes. VHL-related tumors
may present as apparently sporadic but harboring a VHL
mutation, so a routine search for VHL-related tumors and
VHL mutations should be considered in these cases. In
addition, large germline VHL deletions, including that of
the HSPC300 gene, predisposes patients to RCC in VHL,
and biallelic somatic inactivation of the VHL gene may lead
to sporadic RCC (28). Thus, RCC should be actively
searched in VHL cases because it has become the most
common cause of death (77). Conversely, VHL disease is the
main cause of inherited RCC. In addition, marked intra-
familial phenotype variation may be observed and can
reflect established genotype-phenotype correlations for
PHEO and RCC risks (28). VHL testing is indicated for
VHL cases and VHL-similar phenotypes, for all cases with
apparently sporadic PHEO because a high prevalence of
VHL germline mutations has been reported in these
patients, and for familial PHEO cases. Currently, the
surgical approach to VHL-associated PETs has utilized
laparoscopic organ-sparing resection (79). Furthermore,
robot-assisted laparoscopic partial adrenalectomy has been
used recently in the surgical treatment of PHEO/VHL to try
to preserve the adrenal cortex and avoid adrenal insuffi-
ciency (80). Recently, VHL cases with PETs were shown to
be significantly associated with blood group ‘‘O,’’ which
may be useful in selecting VHL cases who are at higher PET
risk (81). Clinical screening for PHEO in VHL should start at
early ages by measuring plasma normetanephrine, mainly
in families at high risk (28). PHEO in patients with VHL
should be actively sought in at-risk family members because
it may mimic stress conditions, and it is frequently
subclinical (82). Anti-angiogenic drugs have been tested in
patients with advanced RCC/VHL and are also potentially
useful for VHL-associated PETs and malignant PHEOs.
Moreover, new targets for novel potential medical treat-
ments in VHL have been found (28). Recently, long-term
disease control with sunitinib has been reported in a patient
with metastatic PETs associated with VHL disease (83).
Carney complex
CS is an autosomal dominant MEN syndrome that affects
the adrenal, pituitary, and thyroid glands and the gonads.
PITs leading to GH hypersecretion and gigantism/acrome-
galy are usually observed. Papillary and follicular thyroid
tumors, large-cell calcifying Sertoli cell tumors and adrenal
carcinoma have also been described (84). Furthermore,
benign primary pigmented nodular adrenocortical disease
leading to Cushing’s syndrome is frequently reported in CS.
Because CS shares abnormalities with Peutz-Jeghers syn-
drome, a differential diagnosis is needed, and restricted
clinical criteria should be applied (36). CS involves at least
four endocrine glands, and a differential diagnosis with
MEN1, MEN2 and MEN4 should be performed to allow for
the adequate management of these patients. PITs in CS may
occur in early life and present rapid growth (29,37). Several
non-endocrine tumors are typically associated, such as heart
myxomas; skin and breast, cutaneous and neural myxoma-
tous tumors; psammomatous melanotic schwannomas; and
virilizing ovarian stromal tumors. Additionally, lentigines
in the face, lips, eyelids, conjunctiva and oral mucosa are
often observed in CS (85,86). CS is caused by germline
PRKAR1A mutations, which is located at 17q13, and two-
thirds of affected cases present a heterozygous germline
PRKAR1A mutation. More than 120 PRKAR1A mutations
have been reported so far (27,85). A second putative disease-
causing mutation was reported on chromosome 2p and may
explain patients with no mutation in PRKAR1A, although
this gene was has not been fully characterized to date
(29,37,55). The second locus at chromosome 2p16, to which
most (but not all) of the remaining affected families are
mapped, is also involved in the molecular pathogenesis of
CS tumors, as demonstrated by multiple genetic changes at
this locus, including LOH and copy number gain (36).
Despite the genetic heterogeneity of the disease, clinical
analysis has not detected any corresponding phenotypic
differences between patients with and without PRKAR1A
CLINICS 2013;68(7):1039-1056 Inherited endocrine tumors
Toledo SP et al.
1043
mutations (36). Recently, it was shown that the differential
roles of PKA catalytic subunits might mediate the CS
phenotype (87,88).
In 2012, ACC was first reported in association with CS in
a large Azorean family harboring the S147G PRKAR1A
mutation (88). A second CS patient with ACC presented a
germline heterozygous PRKAR1A mutation that created a
premature stop codon in exon 2 (p.Lys32Argfs*12), and a
cortisol/androgen-secreting 8.5-cm tumor was detected.
ACC was confirmed, and there were pigmented micro-
nodules typical of PPNAD in the adrenal gland adjacent to
the ACC (89). In two cases, the unilateral ACC co-secreted
androgen and cortisol, whereas benign secreting tumors
caused cortisol excess only. The large size of ACCs and the
occurrence of metastasis demonstrate its malignant nature.
Thus, doctors and patients should be aware of this rare,
devastating event in association with CS (90). Moreover,
cardiac myxoma, which is a genetic source of multiple
strokes in CS, has been successfully removed (91).
Neurofibromatosis type 1
This syndrome is a tumor inherited condition that
presents PHEO/paragangliomas in 5% of cases and in up
to 13% of autopsies. NF1 is usually diagnosed at early ages
in response to the presence of neurofibromas, cafe´-au-lait
skin spots, skinfold freckling, iris Lisch nodules, optic
pathway gliomas, and bone dysplasia. Malignant peripheral
nerve sheath tumors, other gliomas, gastrointestinal stromal
tumors, gastric carcinoids, juvenile myelomonocytic leuke-
mia, glomus tumors, and astrocytomas may also be present
(92-94). NF1 has almost 100% penetrance by the age of 5
years and is relatively frequent, affecting 1 of 3,500
individuals worldwide, and it is caused by the inactivation
of the NF1 tumor suppressor gene that encodes neurofi-
bromin protein. NF1 is a large gene and has one of the
highest known mutation rates in man, and up to 50% of NF1
cases have de novo mutations that may give rise to a mosaic
phenotype. Inactivating NF1 mutations lead to decreased
cellular neurofibromin levels that may predispose patients
to neoplasias (29). In 216 NF1 cases with PHEO/paragan-
glioma, 96% had PHEO, and 6% had paragangliomas, all
of which originated from the sympathetic system.
Additionally, 9% of the PHEOs were malignant, and the
mean age at diagnosis was 42 years. A high degree of inter-
and intra-familial phenotype variation was also noted (29).
Screening for the NF1 gene in apparently sporadic NF1
cases has been recommended (30). PETs may occur in up to
5% of NF1 cases, are usually ,1.0 cm and must be actively
observed (77). The NIH clinical diagnostic criteria for NF1 is
based on the finding of two or more of the following
features: six or more cafe´-au-lait macules with diameters
.5 mm in prepubertal patients and .15 mm in postpuber-
tal patients; two or more neurofibromas of any type or one
plexiform neurofibroma; axillary or inguinal freckling; optic
glioma; two or more Lisch nodules in the iris; a distinctive
osseous lesion, such as sphenoid wing dysplasia or
pseudarthrosis; or a first-degree relative diagnosed with
NF1 (95). Mild clinical forms of NF1 presenting only two
typical features may be missed, and genetic testing is
currently offered by only a few centers, mostly because of
the large size of the NF1 gene (60 exons). The origin of bone
lesions and osteopenia/osteoporosis associated with NF1
has recently been investigated. NF1 germline mutations
lead to altered neurofibromin production and unrepressed
RAS, which acts on the osteoblasts/osteoclasts, leading to
bone mineral loss and eventually to osteopenia/osteoporo-
sis (96). In addition, mice lacking Nf1 in osteochondropro-
genitor cells display skeletal dysplasia similar to patients
with NF1 (97). In sum, there is a relatively high prevalence
of NF1 in human populations, and a routine search for
PHEO/paraganglioma and PETs should be performed in all
cases.
Tuberous sclerosis
This is a multisystem disorder characterized by multiple
hamartomas in the brain, skin, heart, kidneys, and lung.
Epilepsy, learning difficulties, behavioral problems, and
autism are also frequent. Renal angiomyolipomas are
common and can ultimately lead to renal failure, although
renal cysts and RCCs may also be found. Cardiac
rhabdomyomas, lung lymphangioleiomyomatosis, melano-
tic macules, facial angiofibromas, and patches of connective
tissue nevi have been frequently reported. TSC presents a
wide clinical spectrum, and some patients may have
minimal symptoms with no neurologic disability (98,99).
TSC type 1 (TSC1) is caused by a mutation in TSC1 located
at 9q.34 (hamartin), and TSC type 2 (TSC2) is caused by
mutations in TSC2 located at 16p.13 (tuberin). Overall, 20%
of affected cases have TSC1, and the remaining 80% present
TSC2, which is usually more severe. A definitive diagnosis
of the TSC complex may require two or more distinct lesion
types, rather than multiple lesions of the same type in the
same organ system. A clinical diagnosis is not usually
difficult to perform, although a few cases may not fulfill the
criteria. Couples with more than one child with a TSC
complex, no extended family history, and no clinical
features of a TSC complex are likely to have germline
mosaicism for TSC. Germline mosaicism, which is fortu-
nately rare, will not be suspected based on either diagnostic
criteria or molecular testing until a couple has multiple
affected children. Families with one affected child may
include a small (1-2%) possibility of recurrence, even for
parents who present no evidence of a TSC complex after a
thorough diagnostic evaluation (95). In addition, angiomyo-
lipomas are benign mesenchymal tumors originating from
the kidney and adrenal glands and have been frequently
reported in TSC. PETs in TSC and are usually small
(,1.0 cm) and malignant (77). At present, the therapeutic
approach to TCS is based on mTOR inhibitors (100). Because
PETs in TSC are usually small and malignant, patients
should be routinely screened for them by endoscopic
ultrasound.
Li-Fraumeni syndrome
This condition is rare, characterized by multiple endo-
crine and non-endocrine tumors, and has a high penetrance
(101). The usual criteria for identifying LFS cases and
performing genetic testing are based on the following: 1) a
patient with sarcoma or a first- or second-degree relative
affected before 46 years of age; 2) an index-case with
multiple primary tumors, two out of three tumors, with the
first occurring before 36 years regardless of family history;
and 3) an index-case with ACC regardless of the onset age
or family history (101). An estimated 50% of LFS cases will
develop tumors before 30 years of age, and most (.90%)
will present a LFS-related tumor at 70 years of age. Up to
70% of typical LFS cases harbor a germline mutation in the
P53 tumor suppressor gene, although many LFS cases are
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caused by de novo mutations, and copy number variations
are exceedingly high (101). Data from the IARC TP53
database showed that cases with P53 mutations are prone
to present rhabdomyosarcomas at early ages (,5 yr),
whereas other types of sarcomas occur at any age (102).
More than 300 P53 germline mutations have been reported
in association with the LFS phenotype. Because ACC may
also occur in Beckwith-Wiedemann syndrome, MEN1,
familial adenomatous polyposis coli (FAP), and NF1, a
careful differential diagnosis should be performed (103).
Cases with ACC/LFS were thought to be associated with
P53 missense mutations located in the loops that oppose
the protein-DNA contact surface. Interestingly, the inci-
dence of pediatric ACC in southern Brazil is 10 to 15 times
higher than the worldwide prevalence (104,105). Most cases
(78-97%) exhibit a founding P53 arg337-his (R337H) germ-
line mutation in exon 10 (106). The present data indicate
that these patients have an increased risk of developing
several LFS-related tumors and are an intrinsic part of LFS
(107,108). In southern Brazilian populations, the allele
frequency is very high (0.0015), leading to several hundred
thousand carrier subjects. This prevalence may explain the
high frequency of ACC, colorectal cancer, and other types
of cancers in children and adults living in this geographic
area. The ACC penetrance in these cases was evaluated at
10%, so IET patients associated with non-endocrine tumors
from southern Brazil are particularly prone to P53 germline
mutations and LFS-related tumors.
Cowden syndrome
This rare condition is characterized by multiple hamarto-
mas in several organs and a high risk of breast and thyroid
carcinomas, although asymptomatic and undiagnosed cases
may occur. The penetrance is 100% by the age of 40 years,
and the phenotype includes skin lesions such as lipomas,
fibromas, hemangiomas, trichilemmomas, acral keratosis,
and typical oral/plantar lesions. Follicular thyroid carci-
noma (3-10% of cases), early breast cancer (25-50%), and
macrocephaly (20-40%) are also found, and the specific
criteria for a Cowden syndrome diagnosis are usually based
on clinical manifestations (109). Furthermore, familial
follicular cell-derived thyroid carcinoma may be associated
with several inherited conditions, as in Cowden syndrome.
This condition is caused by PTEN germline mutations that
occur in 80% of cases, and there is an exon 5 hotspot (110). A
germline epigenetic regulation of the Killin gene has been
shown in cases with both Cowden syndrome and Cowden
syndrome-like phenotypes. Finally, cases of breast carci-
noma associated with thyroid follicular carcinoma may
have Cowden syndrome, and the diagnosis should be
supported by other phenotypic features and genetic testing.
Familial adenomatous polyposis/Gardner syndrome
Familial follicular thyroid carcinoma may occur in
association with familial adenomatous polyposis (FAP),
which is characterized by a large number of intestinal
polyps and is frequently associated with colon carcinoma
(110). This latter condition is also named Gardner
syndrome, and patients frequently present other asso-
ciated neoplasias, such as desmoid tumors and other skin
lesions. Thus, patients with FAP should be routinely
screened for follicular thyroid carcinoma. The disease is
caused by mutations in the APC gene (OMIM, Gardner
syndrome).
Multiple endocrine neoplasia type 2
MEN2 is a dominant inherited tumor syndrome that
comprises MTC, PHEO, and HPT, whereas congenital
megacolon may occur less frequently. MEN2A refers to
cases with at least two of the three main MEN2-related
tumors. MEN2B refers to patients with very aggressive
MTC; PHEO; an absence of HPT; the presence of marfanoid
body habitus, mucosal neuromas, and intestinal gang-
lioneuromas; and an inability to cry tears. FMTC refers to
MEN2 cases with isolated MTC. MEN2 is caused by RET
germline mutations and has a strong genotype-phenotype
correlation, as documented in the first comprehensive
MEN2 study (6-9). This correlation has been confirmed by
several other investigators (17-20,111,112). RET mutation
analysis consistently has a large impact on the clinical
management of MEN2 patients (20). Several key clinical
investigations and review articles are currently available to
provide proper data on the genetic, clinical, pathological,
and molecular aspects of MEN2 (17,48,111,113). Thus, we
will briefly review some recent advances and issues that
may be associated with MEN2.
Recently, exome studies performed in sporadic and
familial MTC patients documented a high prevalence of
RET and RAS mutations and concluded that mutations in
both genes are the main tumor drivers, although they are
mutually exclusive (114,115). Additionally, second or even
third RET mutations coexisting in MEN2 cases have been
reported (116,117). Somatic RET codon M918T mutations
have also been confirmed as a frequent event (,40%) in
sporadic MTC and are usually related to a poor MTC
outcome (118).
Importantly, the 2009 Guidelines on MTC reduced by two
years (from 5 yr to 3-4 yr of age) the age at which the 2001
MEN Consensus recommended performing preventive TTx
in RET 634 codon mutation carriers (8,9). Notably, the
surgical approach should be completed with a dissection of
all lymph nodes from the central compartment when
nodules are .0.5 cm and calcitonin .40 pg/mL. This shift
towards intervention at earlier ages was based on the
finding of micro-MTC in a 2-year-old patient harboring a
RET 634-mutation and another in a 5-year-old child with
metastatic MTC (9,46,47).
There has been some debate regarding RET Y791F and
Ser649Leu variants. So far, these two variants have been
viewed as disease-causing mutations, and TTx has been
recommended in patients carrying the RET Y791F and
Ser649Leu variants (118,119). However, recent findings have
challenged this concept (75,111). Recently, in vitro studies
showed that transfected cells with the RET L790F variant
had no capacity for malignant transformation (120).
Moreover, authorized catalogs such as the ARUP Online
Scientific Resource (www.arup.utah.edu/database/MEN2/
MEN2_welcome.php) and others eliminated Y791F and
Ser649Leu variants from the list of RET mutation-causing
diseases (111). Although further studies might be needed to
clarify this topic, it would be cautious not to recommend
preventive TTx in these cases based only on the presence of
RET Y791F, Ser649Leu, and L790F variants. In 2012, RET
polymorphisms G691S, L769L, S836S, and S904S from
genetic carriers and non-carriers were studied, and they
had no significant impact on the MTC phenotype (121). In
contrast, RET polymorphisms may influence the expression
of RET V804M mutations. Others found that cumulative
SNPs may lead to aggressive MTC phenotypes (122). In
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addition, the SDHD G12S SNP may modulate the MEN2A
phenotype (123). In contrast, RET polymorphisms may
influence the expression of RET V804M mutations.
However, larger sample sizes of control individuals and
affected patients are needed to provide further conclusions
on the clinical significance of these RET variants (121).
Moreover, double RET germline variants were initially
reported in three cases with atypical MEN2B presenting
both a Val804Met (GTG-to-ATG) mutation in exon 14 and a
Ser904Cys (TCC-to-TGC) mutation in exon 15 (22,59,124).
However, in vitro studies of these variants are required to
determine whether these variants are really mutations or
non-synonymous SNP (120). Furthermore, we recently
described the double RET Cys634Tyr/Y791F variant in four
unrelated families with early, aggressive PHEOs associated
with MTCs presenting the usual outcome for RET 634
mutations (22). Based on in vitro studies, we interpreted the
RET 791 variant as a modulating factor of the PHEO/
MEN2A phenotype (22).
Overall, non-cysteine RET codon mutations have a lower
transformation cell capacity than cysteine codon mutations
(111). In addition, some ‘‘weak’’ non-cysteine RET muta-
tions, such as mutations at codons 804 and 883, may
occasionally lead to MTC disease only in the homozygous
condition (125). In particular, RET codon 804 mutations may
lead to a wide range of phenotypes, variable penetrance and
diverse clinical outcomes (126). In addition, V804/E805K,
V804M/Y806C, and V804M/S904C RET mutations can
cause MEN2B disease (124).
RET genetic testing should be performed in all patients
with PHEO, congenital megacolon, MEN2B-related features,
and apparently sporadic MTC cases (8,22,127). Furthermore,
specific RET haplotypes have been confirmed in the last few
years to be involved in congenital megacolon associated
with MEN2 (128,129). Recent data demonstrated that the
two RET protein isoforms, namely RET9 and RET51, are
important factors in the intracellular trafficking and main-
tenance of RET signaling (130). Interestingly, recent clinical
approaches involving numerous RET mutation-positive
MEN2 patients with specific exons or codon disturbances
have been reported (61,131). These investigations provide
new insights into mutation-specific risk profiles and have
improved our understanding of genotype-phenotype corre-
lations in MEN2 (114-116).
An active familial screening for MEN2 is crucial, and
some MEN2 patients and at-risk family members from
Holland have been followed since 1975 (132,133). In Sa˜o
Paulo, Brazil, we have been clinically screening MEN2 cases
and their parents since 1990 and genetically screening since
2002 (59,134).
The association of MTC with papillary thyroid cancer has
been increasingly recognized in many patients, although
new data are needed on the possible molecular mechanisms
underlying this finding (135).
Calcitonin is an excellent serum tumor marker for MTC,
although its accuracy is not 100%. However, many other
conditions may lead to increased calcitonin values (136,137).
Accordingly, the MTC risk is 8%, 25%, and 100% in cases
with calcitonin values reaching up to 50 pg/ml, 100 pg/ml,
and above 100 pg/ml, respectively (137). Thus, one should
use 100 pg/ml as the cutoff point to avoid false-positive
calcitonin tests, MTC misdiagnosis, and unnecessary thyr-
oidectomies, as had occurred until a few years ago (136).
The first main clinical manifestation of MTC is a single or
multinodular thyroid disease, and most European authors
recommend routine measurements of serum calcitonin in
thyroid nodules (137). This procedure has several advan-
tages for the diagnosis of MTC. First, cases with false-
positive calcitonin tests can be ruled out, and most patients
will have calcitonin values ,100 pg/ml. Second, calcitonin
measurements are more sensitive than cytology when
searching for MTC, unless calcitonin immunocytochemistry
is routinely applied. Third, 0.5-1% of the thyroid nodules
may harbor MTC, and these cases could otherwise be
missed. Fourth, the adequate recognition of MTC in thyroid
nodules allows the surgeon to perform TTx associated with
a central compartment lymphadenectomy, instead of other
approaches. Fifth, the MTC outcome is favorably affected by
MTC diagnosis at early stages (137).
Several reports have documented a predominance of
specific RET mutation types in restricted geographic areas.
For instance, a high frequency of the RET codon 804
mutation was documented in Italian MEN2 cases, and RET
V804M occurred at high frequencies (59%) in 67 MEN2
cases from Sardinia and surrounding islands (138).
Uncommon RET exon 8 mutations have been described
mostly in Brazil and Greece, so routine RET exon 8 analysis
should be performed, mostly in specific geographic areas of
Brazil and Greece (139,140).
Interestingly, the cortical-sparing adrenalectomy has been
recommended in cases with bilateral adrenal PHEOs, such
as in patients with MEN2 (79,80). This approach has been
performed to avoid secondary life-threatening corticoadre-
nal insufficiency, as noted in the early surgical approaches,
and the retroperitoneoscopic adrenalectomy is considered
the ideal approach for adrenal glands (141). Cortical-sparing
adrenalectomies in patients with bilateral PHEO offer a
postoperative corticoid-free course, although this approach
must be balanced against the risk of local recurrence (79). In
addition, robot-assisted posterior retroperitoneoscopic adre-
nalectomy has been recently applied. In cases with bilateral
total adrenalectomy, the control of adrenal insufficiency
may present actual risks. Therefore, cortical-sparing adre-
nalectomy should be welcomed by all endocrine surgeons,
even when considering a 10-20% risk of local recurrence
over the long run. So far, this surgical approach has been
restricted to only a few centers.
The RET protein has been considered as a potential
therapeutic target in sporadic and hereditary MTC cases
with local and distant metastasis (48). Currently, treatment
with tyrosine kinase inhibitors should be offered to
metastatic MTC patients, and several drugs have been
tested, such as sunitinib and vandetanib (142).
Multiple endocrine neoplasia type 1
MEN1 is a highly complex inherited tumor syndrome
associated with at least 20 different types of tumors. The
three main MEN1-associated neoplasias are HPTs (90-
100%), PITs (10-60%), and PETs (60-70%), although cuta-
neous (30-85%) and adrenal tumors (20-40%) are also
frequently found (5,10,57,58). In patients with PETs/
MEN1, the NF-PETs (up to 50%), gastrinomas (40%), and
insulinomas (10%) are the most frequent tumors (10,58).
MEN1 is caused by germline mutations in the MEN1 tumor
suppressor gene, and more than 1,300 germline and somatic
mutations have been described so far. MEN1 mutation
analysis is useful for confirming a clinical diagnosis,
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allowing the genetic screening of at-risk family members and
proper genetic counseling (11). MEN1 screening is usually
offered to all at-risk relatives, allowing early diagnosis and
treatment. Several review articles on MEN1 are available
(5,8,10,48,57,58,143). Thus, we will focus on current advances
and specific issues relating to MEN1.
As noted, the genetic screening of asymptomatic MEN1
mutation carriers was considered to have a low impact on the
clinical management of MEN1 until a few years ago (8). Recent
data demonstrated that MEN1 screening has a substantial
impact on the management of MEN1 (15,16,33,48-
50,58,72,144). Thus, this procedure allows us to rule out
MEN1 non-mutation carriers and MEN1 phenocopies from
annual clinical screening. PTx will benefit most HPT/MEN1
cases, and preventive thymectomy will prevent the develop-
ment of highly malignant and relatively frequent (up to 2.6%)
thymic carcinoid (8). Early treatment of GH-secreting MEN1-
associated PITs may prevent the development of gigantism.
Early diagnosis and treatment in gastrinoma/MEN1 cases
may lead to long survival and a good quality of life, and
malignant NF-PETs/MEN1 may be submitted to early
curative/preventive surgery (8,15,16,29,33-35,48-50,58). A pro-
spective study involving MEN1 mutant gene carriers showed
that periodic follow-ups allowed for early diagnosis and
treatment because MEN1-related tumors were recognized up
to 10 years before clinical disease (144). Additionally, genetic
testing decreased the mortality and morbidity of MEN1
patients, as shown in a study that included 258 MEN1-
mutation positive carriers (145). Furthermore, death rates and
morbidity in cases with malignant gastrinomas/MEN1 have
decreased significantly after medical treatment with ome-
prazole or similar drugs (58).
Importantly, MEN1 screening should be offered to all
first-degree family members who are at risk (50%) of
carrying a MEN1 germline mutation, and clinical screening
for MEN1-associated tumors should start at the ages
recommended by the 2012 MEN1 Clinical Practice
Guidelines (10). Another important topic is the ethics
involved in MEN1 testing (12).
A recent meta-analysis verified that the prevalence of
PITs in MEN1 varies from 10% to 60%. PIT appearing as the
first clinical manifestation of MEN1 may occur in up to 10%
of cases; in these cases, syndrome recognition may be
substantially delayed (146). PIT in MEN1 may occur in
childhood, have rapid growth and development, be highly
aggressive, and exhibit often invasive behavior, and most of
these tumors are secreting macroadenomas at diagnosis.
Prolactinoma is prevalent (80%), and the majority of the
remaining cases are GH-secreting tumors, although non-
functioning PITs (17%) may occur (20,43,146,147). The
majority of MEN1/prolactinomas are benign, although rare
cases may present with metastasis [297]. The normalization
of pituitary hypersecretion is much less frequent in MEN1/
PIT patients than in their SET counterparts. In addition, PIT
cancer patients may need to be treated with temozolomide
(146,148). A transcriptome tumor profile for a 5-year-old boy
with prolactinoma/MEN1 from 2000 disclosed new genes
that may lead to early PIT disease (149). Based on this
specific case, both the 2001 Consensus and the 2012
Guidelines recommended that screening for PITs in MEN1
(prolactin and GH measurements and pituitary MRI) should
start by the age of 5 years (8,10).
Recently, an NIH group investigated 19 patients with
MEN1-associated ACTH- and non-ACTH-secreting tumors,
and their etiology was determined in 14 of these cases (150).
Eleven cases had Cushing’s disease; three had ACTH-
independent Cushing syndrome; three cases simultaneously
had an ACTH-secreting tumor leading to Cushing’s disease
and non-secreting PIT microadenoma. Two of the three
MEN1 patients with ACTH-independent CS also had ACC,
and no ectopic ACTH secretion was identified. The etiology
of hypercortisolism could not be defined in five patients,
whereas in three cases, hypercortisolism appeared to
resolve spontaneously (150).
The frequency of MEN1 mutations in MEN1-related
tumors and their SET counterparts has been revised.
MEN1 shows biallelic inactivation in 30% of some types of
common variety endocrine tumors (e.g., parathyroid ade-
noma, gastrinoma, insulinoma, and bronchial carcinoid) but
only 1-5% in sporadic PITs (151). Most functioning PETs in
MEN1 are represented by gastrinomas (50-60%) and
insulinomas (10%), and the first therapeutic option is
essentially surgical (5,10,33-35). PETs in MEN1 are fre-
quently found at the duodenum and rarely at the pancreas;
they are usually malignant (60%), small (,1 cm) and
multicentric; they are located on the duodenal mucosa
(80%). PETs are the main cause of death of patients with
MEN1 (60%) (33,35). Surgical approaches to gastrinomas
frequently lead to no real cure, unless the surgery can be
performed very early, before metastases. The main surgical
alternatives are total and subtotal pancreatectomy, depend-
ing on the size and localization of the NF-PETs frequently
associated with duodenal gastrinomas. The first option
includes duodenotomy with resection of small and multiple
duodenal gastrinomas, distal 80% subtotal pancreatic resec-
tion, and enucleation of lesser tumors in the head of the
pancreas. Alternatively, pylorus-preserving pancreatoduo-
denectomy or pancreatoduodenectomy, as in the Whipple
procedure, are performed in cases with large tumors
localized in the head of the pancreas or with diffuse disease
and all pancreatic tissue forbidding enucleation. The
pancreatic tail may be spared in cases with limited local
disease and normal endocrine and exocrine pancreatic
functions. Exceptionally, a pancreas-preserving total duo-
denectomy has been performed in a patient with gastri-
noma/MEN1. This surgical procedure, developed by
Imamura et al., is invasive and complex and its use is still
very limited. In patients with Zollinger-Ellison syndrome,
the surgical procedure should be complemented by the
excision of duodenal gastrinomas and regional lymph node
metastases (33-35,152). Partial pancreatectomy, total pan-
creatoduodenectomy, and subtotal pancreatectomy-asso-
ciated with resection of the small duodenal tumors
(multiple nodulectomies) are the surgical options (33-
35,152-154). In addition, gastric carcinoids are frequent in
gastrinoma/MEN1 and require vigilance and adequate
therapy (33).
There is a long-standing controversy as to the optimal
timing for surgery in gastrinoma/MEN1 (77). Most doctors
prefer to intervene surgically in gastrinoma/MEN1 cases
presenting tumors larger than 2-3 cm. Conversely, a group
from Uppsala, Sweden has significant clinical and surgical
experience with MEN1, and they recommend surgery
in PET/MEN1 cases presenting tumor dimensions as small
as 1.0 cm (33,35,153,154). Because PETs are the second
most common disease in MEN1, they play a pivotal role in
the life expectancy and quality of life of MEN1 patients.
Thus, screening with biochemical markers and endoscopic
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ultrasound is recommended for early PET detection in
asymptomatic MEN1-mutation positive cases. Surgery is
currently recommended for all PET cases with tumors larger
than 1.0 cm and no metastases, including NF-PETs. The
latter strategy employs early and aggressive surgery before
metastases can develop, which substantially reduces the risk
for tumor recurrence and malignant progression (33-
35,153,154). More recently, a high prevalence of combined
NS-PET and gastrinoma occurrence has been documented,
and patients were approached by distal 80% subtotal
pancreatic resection associated with tumor enucleation at
the pancreatic head. In Zollinger-Ellison syndrome, duode-
notomy followed by excision of duodenal gastrinomas
together with a clearance of regional lymph node metastases
is recommended (152).
Most NF-PETs in MEN1 have a highly malignant
behavior and are located at the pancreas (8,10). Thus, tumor
serum markers such as PP and chromogranin-A have
become increasingly important for the early detection of
NF-PETs (153,154). Patients may also have increased levels
of insulin/proinsulin, glucagon, and VIP values, without
hormone excess syndrome (154). Studies of NF-PETs/
MEN1 in the French GTE register revealed a low (4%)
metastasis rate for tumors #10 mm and notably higher
metastasis rates (15–52%) for larger tumors (155-157).
However, the authors recommended surgery for NF-PETs
greater than or equal to 2 cm, although they reported a 15%
mortality risk from pancreatic surgery (155-157).
Conversely, surgery for NF-PETs around or greater than
1.0 cm has been recommended by others because the
metastasis rate is unacceptably high for larger tumors, and
surgery has been performed in rather large series without
mortality (35). As already mentioned, the preference of the
Swedish group is to operate on functioning and NF-PETs in
MEN1 using an early, aggressive surgical approach before
metastases have developed. Excellent results have been
reported for a long time with this approach (33,35,153,154).
The surgical strategy is based on distal 80% subtotal
pancreatic resection associated with the enucleation of
tumors located in the head of the pancreas (152).
MEN1-related insulinomas are mostly benign (90%) and
may develop at very early ages (10,153). The optimal timing
to start clinical screening for insulinoma in MEN1 mutation
carriers is 5 years of age (8,10). The simultaneous occurrence
of insulinoma and multicentric NF-PETs is frequent in
patients with MEN1. In addition, subtotal pancreatectomy
associated with tumor enucleation at the pancreatic head is
usually performed in cases with the MEN1/insulinomas. In
conclusion, the early diagnosis and surgical treatment of
PETs/MEN1 are critical topics for achieving a cure, as
previously reported (33,35,153,154).
The timing for starting genetic screening in at-risk family
members was first established by the 2001 consensus. Thus,
clinical screening should start at 5 years of age for PITs and
insulinomas in MEN1-mutation positive patients; at 8-10
years for HPT; and by 20 years for gastrinomas and NF-
PETs, although the 2012 Clinical Practice Guidelines
reduced the age for the latter procedure, which should
begin at 10 years (8,10).
MEN1-associated primary HPT has a high penetrance,
and almost all MEN1 cases will present HPT by 50 years of
age, although most cases will exhibit the disease by 20 years
of age (5,10,31). HPT/MEN1 usually develops 30 years
earlier than its SET counterpart, although most patients will
exhibit the disease by 20 years of age (5,10,31). This
condition affects all four parathyroid glands and is a
monoclonal event, and it is frequently the first MEN1
presentation. Patients usually have early and severe bone
demineralization and renal complications that were con-
sidered an important cause of death, at least until 1998
(45,46,158). It is still a matter of debate how to operate on
HPT/MEN1 patients (48,51). PTx is advised by most
surgeons and clinicians as the optimal approach to HPT/
MEN1. However, there is a dispute as to whether subtotal or
total PTx would be optimal for treating this condition
(51,57,159,160). Subtotal PTx is largely applied, which
usually leads to low rates of secondary hypoparathyroidism
and may involve lesser surgical complications. However,
one-third of cases may present HPT relapse/recurrence
during the post-surgical follow-up, and substantial surgical
difficulties may appear during parathyroid re-intervention
(159). Conversely, total PTx followed by parathyroid auto-
transplant to the non-dominant forearm is a valuable
alternative and may have some advantages (48,51,160).
First, post-surgical hypoparathyroidism is most frequently
observed until 6-12 months after PTx. Subsequently, by
months 12-15 after PTx, most patients will recover their
normal serum PTH and calcium values, allowing the end of
oral calcium and vitamin D supplementation (49,50). Our
data have been confirmed by others (161). Thus, successful
parathyroid auto-implants that were either cryopreserved or
performed immediately after total PTx may secrete sufficient
physiological amounts of PTH and achieve euparathyroid-
ism (49,50,161,162). Additionally, the rate of relapse/recur-
rent HPT after total PTx is usually lower than in subtotal PTx,
and when it occurs, the partial excision of the parathyroid
implant requires only local forearm anesthesia (160).
In addition, there is some controversy as to when to
operate on HPT/MEN1 cases, although several groups
prefer to perform PTx as soon as there is a classical
indication to recommend surgery (52,57,163). Notably, the
criteria used to recommend PTx in HPT/MEN1 cases are
the same as those used for sporadic primary HPT and
include the presence of albumin-corrected total calcium at
1 mg/dl higher than the upper normal ranges, renal calculi,
age at diagnosis lower than 50 years, and osteoporosis (163).
Thus, severe bone mineral losses (Z-score ,-2.0 or a T-score
,-2.5 SD) constitute a classical recommendation for PTx in
HPT/MEN1 cases (44,45,49,50). In addition, PTx usually
leads to a substantial decrease in the gastrin serum levels in
cases with associated gastrinoma and allows for the
performance of concomitant preventive thymectomy
(8,10,164). Alternatively, some authors prefer to postpone
PTx in apparently asymptomatic primary HPT cases (31).
Lourenc¸o Jr et al. recently suggested that the annual bone
mineral density (BMD) analysis in HPT/MEN1 cases
should start at ages as early as 20 years and include all
three main bone sites because the proximal one-third of the
distal radius (1/3DR) is severely affected in patients with
HPT/MEN1 (44,45,165). If the 1/3DR is not approached,
some cases with severe bone mineral losses may be missed
(44,45,49,50). In addition, a short-term BMD improvement
was recently noted after total PTx followed by parathyroid
auto-transplant in HPT/MEN1 cases (49). As far as we
know, only two studies have consistently evaluated BMD
values after PTx in cases of MEN1-associated HPT (49,165).
Concordantly, BMD exhibits a sharp short-term recovery at
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the lumbar spine and femoral neck but not at the 1/3DR
(49,50,165).
Benign cutaneous tumors (collagenomas and angiofibro-
mas, .70-80%) are highly prevalent in MEN1 and are an
excellent clinical indicator for the early clinical diagnosis of
MEN1 (8). Additionally, adrenal tumors are frequently
found in patients with MEN1 (.40%) (5,10). Interestingly,
glucose-dependent insulinotropic peptide receptor over-
expression in adrenocortical hyperplasia without LOH at
the 11q13 locus has been reported in MEN1 syndrome (166).
Adrenal tumors/MEN1 are mostly non-secreting benign
neoplasias, however periodic screening for secreting tumors
and ACC are currently recommended (8,10).
Ongoing studies on the clinical heterogeneity in MEN1 are
attempting to explain the marked intra- and inter-familial
phenotypic variations. MEN1 non-synonymous SNPs,
sequencing variants in other genes, copy number variations,
iRNA, and epigenetic factors (e.g., DNA methylation) have
been claimed as potential phenotypic modifiers (143).
Accordingly, tissue-specific susceptibilities to MEN1-related
tumors deserve further investigation, and possible genotype-
phenotype correlations have been recently revised (143).
Recently, Zhang et al. and Lewis et al. confirmed that
MEN1 patients have decreased insulin sensitivity, a higher
prevalence of impaired fasting glucose compared with
controls unrelated to MEN1 manifestations, and an
increased risk of cardiovascular disease (167,168). Thus, it
is important to search for glucose intolerance and diabetes
in all MEN1-mutation carriers.
Carcinoid tumors are frequent in patients with MEN1 and
may be mostly found in the gastric area (10%), bronchi (2%),
and thymus (2%) (169). Thymic carcinoids are fast growing,
highly aggressive malignant tumors and are prevalent (up
to 3.5%) in some MEN1 series (170). Most affected cases are
in heavy smoking males. Conversely, bronchial carcinoid/
MEN1s have a less aggressive outcome and are more
prevalent in women (169). Preventive transcervical thy-
mectomy during PTx for HPT/MEN1 is usually effective in
preventing the development of thymic carcinoids, although
in other series, this surgical approach was not sufficient to
prevent local and distant metastases (156,171).
Multiple endocrine neoplasia type 4
Not all patients with a MEN1 phenotype harbor a
germline MEN1 mutation, even when considering patients
with large deletions and intronic mutations. Thus, a new
gene(s) has been proposed for cases with MEN1-like
phenotypes and no MEN1 mutations. Concordantly, a
female index-case with acromegaly from a pituitary GH-
secreting tumor associated with primary HPT was
described as carrying a germline mutation in the CDKN1B
gene in 2006. In addition, her mutation-positive relative had
a renal angiomyolipoma (54). Several other similar cases
with MEN1-like phenotypes have been reported, support-
ing the idea that all MEN1 cases without MEN1 germline
mutations should be screened for the CDKN1B gene
(54,172,173). However, due to the limited number of affected
cases reported so far (10 cases), the MEN4 phenotype has
not been fully established (54).
Inherited pancreatic endocrine tumor syndromes
Familial PETs may occur in patients with MEN1, CS, VHL
disease, NF1, and TSC (77). The relative frequency of PETs
is higher in patients with MEN1 and VHL compared with CS,
NF1, and TSC. Preoperative assessment of the pancreas in
MEN1 is highly critical because it may allow surgeons to
better plan the approach and evaluate when and how to
operate (167). Specifically, familial gastric stromal tumors
may be found in patients with CS and differ from its SET
counterpart (168). Surgery and radiofrequency ablation have
been utilized to treat liver metastases from midgut and
foregut carcinoids and PETs. Notably, a study of PETs in
these syndromes provided insights into the possible patho-
genesis of sporadic PETs and contributed to the clinical and
therapeutic management of each inherited condition and
their sporadic tumor counterparts.
Isolated familial acromegaly/gigantism
Acromegaly/gigantism has been a long-standing chal-
lenge. In Belgium, patients with acromegaly/gigantism are
3-5 times more prevalent than previously reported, yielding
1 case in 1,064 individuals (174). In 2012, de Herder
described six of the most famous giants ever known in the
last two or three centuries (175). One of these cases had a
genetic predisposition to GH-secreting tumors and har-
bored a germline AIP mutation (65). Most patients with
isolated familial somatotropinoma (IFS) do not harbor
MEN1 germline mutations, but their tumors secrete high
serum levels of GH and are associated with acromegaly/
gigantism (176). The genetic cause of IFS has been linked to
the same gene locus of MEN1, that is, 11q13, although no
MEN1 germline mutation has been verified in these cases.
In 2006, germline AIP mutations were reported in several
IFS cases from Finland; soon after, these data were
confirmed in Belgium and Brazil (41,177). The onset of a
GH-secreting tumor in IFS cases occurs approximately 4-10
years earlier than sporadic PITs and these tumors are highly
aggressive (37). After the AIP discovery, IFS cases have been
referred to as FIPA (26,174). Interestingly, familial somato-
tropinoma leading to acromegaly/gigantism may also occur
in the context of other IET syndromes, such as MEN1, CS,
and autosomal dominant polycystic kidney disease
(178,179).
Familial isolated pituitary adenoma
This entity is an autosomal inherited tumor syndrome
characterized by the presence of a PIT that secretes GH and
prolactin, although non-functioning PITs, Cushing’s dis-
ease, and thyrotropinoma may also occur. PITs in patients
with FIPA differ from sporadic PITs in several respects
because they are more aggressive and expansive and
usually have an earlier onset (,20 yr of age). Young FIPA
patients often harbor macroadenomas that may be partially
resistant to cabergoline therapy (174). The first description
of AIP mutations was performed with a large group of
patients with familial acromegaly/gigantism from Finland
(42). Other authors have published similar data (41,180).
Two Brazilian siblings with acromegaly and GH-secreting
PITs were clinically reported in 2001, and a heterozygous
AIP mutation was documented soon after (42,176). Another
clinically unaffected 41-year-old brother carried this muta-
tion on an apparently non-secreting pituitary micro-nodule
(3 mm) and was documented in imaging studies. His 3-
year-old mutated son was also unaffected (42). Overall, 5%
of all PITs are related to MEN1, FIPA, CS, and MEN4
(26,37). Up to 25% of all FIPA cases harbor a germline AIP
mutation, although AIP germline mutations have rarely
been detected in apparently sporadic PITs. However, a high
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prevalence of AIP mutations in macroadenoma cases
younger than 30 years of age (10%) and in children
with macroadenomas (.20%) have been verified (180).
Furthermore, FIPA may have a relatively high prevalence in
the general population because it accounts for up to 2-3% of
PITs in some series. In groups at high risk of AIP mutations,
genetic screening is recommended because it may lead to
early diagnosis and treatment (180). Recently, an interna-
tional consortium investigated 96 patients with germline
AIP mutations and PITs and 232 matched AIP mutation-
negative acromegaly controls. The group concluded that the
first symptoms occurred in children/adolescents in 50% of
cases, and most tumors were macroadenomas (93.3%).
Tumor extension and invasion was common. GH-secreting
tumors in FIPA were predominant (78.1%) and larger, with
higher GH levels and occurrence two decades earlier, when
compared with sporadic PITs (26). Gigantism was more
common in the AIP-mutated group, and several cases
presented less tumor shrinkage with somatostatin analogs
versus the controls. Prolactinoma in FIPA was frequent in
young males patients, and most required surgery or
radiotherapy. These data indicate that the genetic screening
associated with early diagnosis and treatment should be
routinely considered in families with PITs/FIPA (26).
Recently, genetic heterogeneity was suggested to occur in
FIPA (181,182). In addition, the presence of ACC in a FIPA
case suggested that AIP mutations may be lead to non-PIT
tumors (181). In conclusion, AIP mutation analysis is
recommended in young patients with FIPA.
Founding AIP mutations have been described in familial
clusters from Finland, Polynesia, and Ireland. A large family
presenting with multiple individuals with PITs secreting
GH, prolactin, or both was reported in northern Finland.
There were three cases of acromegaly or gigantism, and
their genealogy could be traced to the 1700s. The phenotype
was first postulated to represent a hereditary predisposition
to pituitary adenomas (PAPs) with very low penetrance. A
second family had two affected cases in two generations
with somatotropinoma. In comparison to patients with
sporadic PITs, patients with PAP were significantly younger
at diagnosis, but there were no significant differences in
tumor size. Six of the 15 patients diagnosed under 35 years
of age (40%) in the population-based series had PAP. More
recently, PAP cases have been referred to as FIPA (41).
Highly aggressive PITs were reported in 2009 in a large
FIPA Polynesian genealogy associated with a founding AIP
mutation (183). In 2011, the AIP arg304-to-ter mutation was
identified in DNA extracted from the teeth of an Irish
patient with gigantism who lived from 1761 to 1783 (65).
Decades prior, Harvey Cushing first examined the skeleton
of this particular case described in 2011, identified an
enlarged pituitary fossa, and ascribed his gigantism to a
PAP. The same AIP germline mutation was identified in
four contemporary northern Irish families who presented
with gigantism, acromegaly, or prolactinoma, and they also
harbored the same haplotypes. Thus, these individuals were
postulated to share a common ancestor who lived approxi-
mately 57 to 66 generations earlier (65).
Familial Cushing’s syndrome
This condition may be associated with MEN1 and CS and
is rarely associated with FIPA; however, it may also occur in
McCune-Albright syndrome (184). Accordingly, familial
pituitary ACTH-secreting tumors leading to Cushing’s
disease may occur in MEN1 syndrome (6). In addition,
non-ACTH secreting Cushing’s syndrome from adrenocor-
tical carcinomas and adenomas may also occur in MEN1,
and a few cases may present both ACTH-secreting and non-
ACTH secreting tumors (150). Furthermore, pigmented
adrenal hyperplasia is a non-ACTH secreting tumor
frequently observed in patients with CS (37).
Familial papillary thyroid carcinoma
FPTC is usually more aggressive than sporadic PTC and
may be associated with FAP/Gardner syndrome and
Cowden syndrome (185). Over a decade ago, the search
for FPTC susceptibility genes identified the following six
potential loci: MNG1 (14q32), TCO (19p13.2), fPTC/PRN
(1q21), NMTC1 (2q21), FTEN (8p23.1-p22), and the telo-
mere-telomerase complex. Genes such as RET, TRK, MET,
and TSHR were ruled out. The results have been partially
contradictory, and further large-scale genetic studies using
new molecular screening tests are warranted to elucidate
the underlying genetic basis of FPTC (110).
Familial isolated hyperparathyroidism
Most cases with primary HPT (95%) are sporadic; the
remaining patients have inherited forms of HPT. At present,
most HPT cases are asymptomatic (80%), whereas 20% are
symptomatic cases (31). FIHPT may occur as part of either
MEN1 syndrome or FIHPT/jaw tumor syndrome (HPT/JT)
caused by HRPT2 germline mutations. Interestingly, HRPT2
mutations have been reported in 15% of parathyroid
carcinoma cases, which rarely lead to HPT (186). HPT-JT
is a rare inherited cancer syndrome that is usually
associated with HPT and ossifying tumors of the maxilla/
mandible, and it may harbor a germline HRPT2-inactivating
mutation. HRPT2 encodes a 531-amino acid protein called
parafibromin (186). Mild FIHPT may also occur in familial
hypocalciuric hypercalcemia (FHH), an autosomal domi-
nant disease with relative hypocalciuria. Most FHH cases
are caused by a heterozygous CASR inactivating mutation,
although homozygous or compound heterozygous CASR
mutations can lead to severe neonatal HPT. Moreover, a
homozygous CaSR germline missense mutation has been
reported in FHH phenotypes, although most heterozygotes
are normocalcemic. However, many FIHPT cases have no
mutation in the MEN1, HRPT2, or CASR genes, suggesting
that additional gene(s) are be involved.
Familial primary aldosteronoma
FPA is a relatively underdiagnosed condition, and it is
the most frequent cause (5-15%) of secondary hypertension
in adults (187). FPA has been mostly detected in non-
smoker hypertensive patients. Due to a higher rate of
cardiovascular complications relative to essential hyperten-
sion, the screening of at-risk groups for FPA is recom-
mended (188). FPA is confirmed by a lack of aldosterone
suppressibility following a sodium-loading test. CT scan-
ning and adrenal venous sampling usually detect a
unilateral source of aldosterone excess. Laparoscopic adre-
nalectomy is the treatment of choice, with excellent out-
comes and low morbidity, in comparison with older, open
approaches. Three genetic forms of FPA have been
described so far, including familial hyperaldosteronism
type I (FH-I), also known as glucocorticoid-remediable
aldosteronism (GRA); familial hyperaldosteronism type II
(FH-II); and familial hyperaldosteronism type III (FH-III).
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Patients with FH-I/GRA have hypertension, high ACTH-
dependent aldosterone secretion, renin suppression, and
high levels of 18OH-cortisol and 18 oxocortisol. The genetic
cause is an unequal recombination of CYP11B1 (11-b-
hydroxylase)/CYP11B2 (aldosterone synthase) that leads
to a chimeric CYP11B gene containing CYP11B1 sequences
(including the promoter) at its 59 end and CYP11B2
sequences at its 39 end (187). This condition is very rare,
and most patients develop severe hypertension in early life,
although clinical heterogeneity is frequent. Genetic testing
for FH-I/GRA is recommended for cases presenting with
FPA before 20 years of age, a family history of FPA, and
stroke at a young age (,40 years) (187). In 2011, a high
prevalence of FH-I/GRA among hypertensive children in
Chile was reported (3.1%). All cases from four unrelated
families had a high aldosterone/renin ratio and low renin,
whereas hypokalemia and high aldosterone levels were
much less useful as markers of FPA. Genetic testing
overcomes these difficulties, and the most widely used test
is a long PCR-based method that amplifies the chimeric
CYP11B1/B2 gene. FH-II is a non-glucocorticoid-remediable
form of FPA, and it is indistinguishable from sporadic PA.
This condition is relatively frequent (3-4%), and its
molecular basis involves the 7p22 locus. The diagnosis of
FH-II requires the presence of PA to be confirmed in at least
two family members, and FH-I/GRA must be excluded. FH-
II should be considered in hypertensive family members of
PA patients. So far, this new condition was reported in one
family, is characterized by severe hyperaldosteronism and
resistance to common medical therapy, and requires
bilateral adrenalectomy. A germline mutation in the
KCNJ5 gene is the cause of FH-III.
Inherited adrenocortical carcinoma
Inherited adrenocortical tumors (carcinomas and adeno-
mas) may occur in several conditions such as CS, LFS,
Beckwith-Wiedemann syndrome (BWS), MEN1, NF1, FAP,
and McCune Albright syndrome (90,107,108,189). Children
with IACC are usually part of the classical tumor spectrum
of LFS and BWS. The current recommendations regarding
IACC screening and surveillance involve periodic biochem-
ical and imaging studies in the index-cases, mutation
analysis of all relatives who are at risk, and early diagnosis
and surgical intervention.
Familial isolated pheochromocytoma/
paraganglioma
FI-PHEO/paraganglioma has been associated with sev-
eral inherited diseases such as MEN2; VHL; NF-1; and
paraganglioma syndromes types 1, 3, and 4, which are
caused by germline mutations in RET, VHL, NF1, SDH-D,
SDH-C, and SDH-B, respectively (78,91,190). SDHx muta-
tions are responsible for 6% and 9% of sporadic para-
gangliomas and PHEOs, respectively; in addition, they
underlie 29% of pediatric cases and 38% of malignant
tumors. More than 80% of familial aggregations of para-
ganglioma and PHEO are caused by these mutations (191).
In addition, FI-PHEO/paraganglioma has been associated
with TMEM127 and MAX mutations (23,24,25,192). Genetic
screening for PHEO genes has been recommended in all
cases with apparently sporadic PHEO/paraganglioma
because approximately 30% of these patients may harbor a
PHEO-related germline mutation. In a German series of
apparently sporadic PHEOs, frequent mutations in the VHL
and RET were found (57). In contrast, unsuspected germline
mutations occurred in eight cases within a recent Italian
series of 59 patients with apparently sporadic disease. The
eight mutations were found in TMEM127 (n = 4), SDHB
(n = 2), VHL (n = 1), and SDH-C (n = 1). Despite increased
costs, the authors recommended systematic genetic screen-
ing in these patients because it might lead to a stricter
follow-up, early diagnosis of recurrences in index-cases, and
presymptomatic disease detection in at-risk relatives.
In 2012, a high incidence of paraganglioma type 1
syndrome was reported in Trentino, Italy, and affected cases
were characterized by HNPs caused by the SDHD c.341A.G
p.Tyr114Cys mutation. Patients had bilateral or multiple
HNPs that were associated with a low prevalence of PHEO,
malignant forms, and a high tumor penetrance. A common
ancestor was dated back to the 14-15th century, with the
mutation spreading from the Mocheni Valley isolate, which
represents 1.5% of the region’s population (64).
Pre-surgical care in asymptomatic FI-PHEO cases has
some particularities. Because sustained or paroxysmal
hypertension is detected in 90% of PHEO cases, a-
adrenoceptor-blocking agents have been successfully admi-
nistered to prevent hypertension before and during surgery
for PHEO. With the discovery of asymptomatic PHEOs,
many of them FI-PHEOs, this condition has been more
frequently diagnosed than it was before modern imaging
techniques were available. Accordingly, accumulated
experiences with the use of a-adrenoceptor-blocking agents
in asymptomatic PHEOs support the benefits of this
procedure. Finally, cases with bilateral FI-PHEO are
currently recommended to undergo cortical-sparing surgery
using the retroperitoneoscopy access, which has a low
recurrence rate and avoids lifelong cortisone substitution
therapy in most cases. Thus, it would be prudent to
recommend this surgical technique to all patients with
bilateral PHEO.
Finally, more recent IET reviews have become available,
and they provide further insights into these inherited tumor
diseases (193-198).
& ACKNOWLEDGMENTS
SPAT is a Senior Investigator and is partially supported by a National
Research Council (CNPq) fellowship and grant (401990/2010-9); RAT is
supported by a post-doctoral fellowship from the State Research
Foundation (FAPESP) and presently works at the Cancer Therapy &
Research Center, Health Science Center, Institute for Integration of
Medicine and Science at the University of Texas at San Antonio, TX,
USA. This study was partially supported by CNPq and FAPESP.
& AUTHOR CONTRIBUTIONS
Toledo SP coordinated the review and worked intensively for months on
this review project. Lourenc¸o Jr. DM and Toledo RA reviewed carefully
several articles and collaborated by discussing, commenting and writing
part of the manuscript.
& REFERENCES
1. Leonard JM. Familial endocrine tumors. West J Med. 1980;132(4):352-33.
2. Neumann HPH, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon
A, et al. Evidence of MEN-2 in the original description of classic
pheochromocytoma. New Eng J Med. 2007;357(13):1311-5, http://dx.
doi.org/10.1056/NEJMoa071407.
3. Wermer P. Genetic aspects of adenomatosis of endocrine glands.
Am J Med. 1954;16(3):363-71.
4. Carney JA. Familial multiple endocrine neoplasia: the first 100 years.
Am J Surg Pathol. 2005;29(2):254-74.
CLINICS 2013;68(7):1039-1056 Inherited endocrine tumors
Toledo SP et al.
1051
5. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and
2. Nat Rev Cancer. 2005;5(5):367-75.
6. Mulligan L, Marsh DJ, Robinson BG, Shuffenecker I, Zedenius J, Lips
CJM, et al. Genotype-phenotype correlation in multiple endocrine
neoplasia type 2: report of the International RET Mutation Consortium.
J Intern Med. 1995;238(4):343-46, http://dx.doi.org/10.1111/j.1365-
2796.1995.tb01208.x.
7. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al.
The relationship between specific RET proto-oncogene mutations and
disease phenotype in multiple endocrine neoplasia type 2. International
RET mutation consortium analysis. JAMA. 1996;276(19):1575-9, http://
dx.doi.org/10.1001/jama.1996.03540190047028.
8. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C,
et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2.
J Clin Endocrinol Metab. 2001;86(12):5658-71, http://dx.doi.org/10.
1210/jc.86.12.5658.
9. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al.
Medullary thyroid cancer: management guidelines of the American
Thyroid Association. Thyroid. 2009;19(6):565-612, http://dx.doi.org/10.
1089/thy.2008.0403.
10. Thakker RV, Newey J, Walls GV, Bilezikian J, Dralle H, Ebeling PR. et al.
Clinical practice guidelines for multiple endocrine neoplasia type
1(MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011, http://dx.doi.
org/10.1210/jc.2012-1230.
11. Lips CJ, Ho¨ppener JW. Ethics: Genetic testing for MEN1-whose
responsibility? Nat Rev Endocrinol. 2012;8(10):575-6, http://dx.doi.
org/10.1038/nrendo.2012.164.
12. Toledo RA, Sekiya T, Longuini VC, Coutinho FL, Lourenc¸o DM Jr,
Toledo SP. Narrowing the gap of personalized medicine in emerging
countries: the case of multiple endocrine neoplasias in Brazil. Clinics.
2012;67 Suppl 1:3-6, http://dx.doi.org/10.6061/clinics/2012(Sup01)02.
13. Dammann M, Weber F. Personalized medicine: caught between hope,
hype and the real world. Clinics. 2012;67 Suppl 1:91-7, http://dx.doi.
org/10.6061/clinics/2012(Sup01)16.
14. Carling T, Correa P, Hessman O, Hedberg J, Skogseid B, Lindberg D
et al. Parathyroid MEN1 gene mutations in relation to clinical
characteristics of nonfamilial primary hyperparathyroidism. J Clin
Endocrinol Metab. 1998;83(8):2960-3, http://dx.doi.org/10.1210/jc.83.8.
2960.
15. Lourenc¸o DM Jr, Toledo RA, Coutinho FL, Margarido LC, Siqueira SA,
dos Santos MA, et al. The impact of clinical and genetic screenings on
the management of the multiple endocrine neoplasia type 1. Clinics.
2007;62(4):465-76, http://dx.doi.org/10.1590/S1807-593220070004000
14.
16. Lourenc¸o DM Jr, Coutinho FL, Toledo RA, Gonc¸alves TD, Montenegro
FL, Toledo SP. Biochemical, bone and renal patterns in hyperparathyr-
oidism associated with multiple endocrine neoplasia type 1. Clinics.
2012;67Suppl 1:99-108, http://dx.doi.org/10.6061/clinics/2012(Sup01)
17.
17. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ,
Roeher HD, et al. Multiple Endocrine Neoplasia (EUROMEN) Study
Group. Early malignant progression of hereditary medullary thyroid
cancer. N Engl J Med. 2003;349(16):1517-25.
18. Machens A, Dralle H. Familial prevalence and age of RET germline
mutations: implications for screening. Clin Endocrinol (Oxf). 2008;69
(1):81-87, http://dx.doi.org/10.1111/j.1365-2265.2007.03153.x.
19. Machens A, Dralle H. Multiple endocrine neoplasia type 2: achieve-
ments and current challenges. Clinics. 2012;67 Suppl 1:113-118, http://
dx.doi.org/10.6061/clinics/2012(Sup01)19.
20. Toledo SP, dos Santos MA, Toledo RA, Lourenc¸o DM Jr. Impact of RET
proto-oncogene analysis on the clinical management of multiple
endocrine neoplasia type 2. Clinics. 2006;61(1):59-70, http://dx.doi.
org/10.1590/S1807-59322006000100011.
21. Correia-Deur JE, Toledo RA, Imazawa AT, Lourenc¸o DM Jr, Ezabella
MC, Tavares MR, et al. Sporadic medullary thyroid carcinoma: clinical
data from a university hospital. Clinics. 2009;64(5):379-86.
22. Toledo RA, Wagner SM, Coutinho FL, Lourenc¸o DM Jr, Azevedo JA,
Long uini VC, et al. High penetrance of pheochromocytoma associated
with the novel C634Y/Y791F double germline mutation in the RET
protooncogene. J Clin Endocrinol Metab. 2010;95(3):1318-27, http://dx.
doi.org/10.1210/jc.2009-1355.
23. Burnichon N, Casco´n A, Schiavi F, Morales NP, Comino-Me´ndez I,
Abermil N, et al. MAX mutations cause hereditary and sporadic
pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18
(10):2828-37, http://dx.doi.org/10.1158/1078-0432.CCR-12-0160.
24. Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, et al.
Germline mutations in TMEM127 confer susceptibility to pheochromo-
cytoma. Nat Genet. 2010;42(3):229-233, http://dx.doi.org/10.1038/ng.
533.
25. Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pe´rez L, King EE, et al.
Spectrum and prevalence of FP/TMEM127 gene mutations in pheo-
chromocytomas and paragangliomas. JAMA. 2010;304(23):2611-9,
http://dx.doi.org/10.1001/jama.2010.1830.
26. Daly AF, Tichomirowa MA, Petrossians P, Helio¨vaara E, Jaffrain-Rea
ML, Barlier A, et al. Clinical characteristics and therapeutic responses in
patients with germ-line AIP mutations and pituitary adenomas: an
international collaborative study. J Clin Endocrinol Metab. 2010;95
(11):E373-383, http://dx.doi.org/10.1210/jc.2009-2556.
27. Vezzosi D, Vignaux O, Dupin N, Bertherat J. Carney complex: Clinical
and genetic 2010 update. Ann Endocrinol (Paris). 2010;71(6):486-493,
http://dx.doi.org/10.1016/j.ando.2010.08.002.
28. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a
clinical and scientific review. Eur J Hum Genet. 2011;19(6):617-23.
29. Stratakis CA, Schussheim DH, Freedman SM, Keil MF, Pack SD,
Agarwal SK, et al. Pituitary macroadenoma in a 5-year-old: an early
expression of multiple endocrine neoplasia type 1. J Clin Endocrinol
Metab. 2000;85(12):4776-80, http://dx.doi.org/10.1210/jc.85.12.4776.
30. Bausch B, Koschker AC, Fassnacht M, Stoevesandt J, Hoffmann MM,
Eng C, et al. Comprehensive mutation scanning of NF1 in apparently
sporadic cases of pheochromocytoma. J Clin Endocrinol Metab.
2006;91(9):3478-81, http://dx.doi.org/10.1210/jc.2006-0780.
31. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al.
The natural history of primary hyperparathyroidism with or without
parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;
93(9):3462-3470, http://dx.doi.org/10.1210/jc.2007-1215.
32. Lourenco DM Jr, Coutinho FL, Toledo RA, Gonc¸alvez TD, Montenegro
FLM, Toledo SPA. Biochemical, bone, and renal patterns in hyperpar-
athyroidism associated with multiple endocrine neoplasia type 1.
Clinics. 2012;67 Suppl 1:99-108, http://dx.doi.org/10.6061/clinics/
2012(Sup01)17.
33. Akerstro¨m G, Sta˚lberg P, Hellman P. Surgical management of
pancreatico-duodenal tumors in multiple endocrine neoplasia syn-
drome type 1. Clinics. 2012;67 Suppl 1:173-8, http://dx.doi.org/10.
6061/clinics/2012(Sup01)29.
34. Machado MC. Surgical treatment of pancreatic endocrine tumors in
multiple endocrine neoplasia type 1. Clinics. 2012;67 Suppl 1:145-8,
http://dx.doi.org/10.6061/clinics/2012(Sup01)24.
35. Oberg K. Diagnostic work-up of gastroenteropancreatic neuroendocrine
tumors. Clinics. 2012;67 Suppl 1:109-12, http://dx.doi.org/10.6061/
clinics/2012(Sup01)18.
36. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features
of the Carney complex: diagnostic criteria and recommendations for
patient evaluation. J Clin Endocrinol Metab. 2001;86(9):4041-6, http://
dx.doi.org/10.1210/jc.86.9.4041.
37. Stratakis CA, Tichomirowa MA, Boikos S, Azevedo MF, Lodish M,
Martari M, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B
and CDKN2C mutations in causing pituitary adenomas in a large
cohort of children, adolescents, and patients with genetic syndromes.
Clin Genet. 2010;78(5):457-63, http://dx.doi.org/10.1111/j.1399-0004.
2010.01406.x.
38. Machens A, Gimm O, Hinze R, Hoppner W, Bohem BO, Dralle H.
Genotype-phenotype correlations in hereditary medullary thyroid
carcinoma: oncological features and biochemical properties. J Clin
Endocrinol Metab. 2001;86(3):1104-9, http://dx.doi.org/10.1210/jc.86.3.
1104.
39. Hayashida CY, Alves VA, Kanamura CT, Ezabella MC, Abelin NM,
Nicolau W, et al. Immunohistochemistry of medullary thyroid
carcinoma and C-cell hyperplasia by an affinity-purified anti-human
calcitonin antiserum. Cancer. 1993;72(4):1356-63, http://dx.doi.org/10.
1002/1097-0142(19930815)72:4,1356::AID-CNCR2820720434.3.0.CO;2-
0.
40. Tavares MR, Toledo SP, Montenegro FL, Moyses RA, Toledo RA, Sekyia
T, et al. Surgical approach to medullary thyroid carcinoma associated
with multiple endocrine neoplasia type 2. Clinics. 2012;67 Suppl 1:149-
54, http://dx.doi.org/10.6061/clinics/2012(Sup01)25.
41. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A,
et al. Pituitary adenoma predisposition caused by germline mutations
in the AIP gene. Science. 2006;312(5777):1228-30, http://dx.doi.org/10.
1126/science.1126100.
42. Toledo RA, Lourenc¸o DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti
MG, Moyses CB, et al. Germline mutation in the aryl hydrocarbon
receptor interacting protein gene in familial somatotropinoma. J Clin
Endocrinol Metab. 2007;92(5):1934-7, http://dx.doi.org/10.1210/jc.
2006-2394.
43. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, et al.
Pituitary Disease in MEN Type 1 (MEN1): Data from the France-
Belgium MEN1 Multicenter Study J. Clin. Endocrinol. Metab. 2002;87
(2):457-65, http://dx.doi.org/10.1210/jc.87.2.457.
44. Lourenc¸o Jr DM, Toledo RA, Mackowiak II, Coutinho FL, Cavalcanti
MG, Correia-Deur, et al. Multiple endocrine neoplasia type 1 in Brazil:
MEN1 founding mutation, clinical features, and bone mineral density
profile. Europ J Endocrinol. 2008;159(3):259-74.
45. Lourenco DM Jr, Coutinho FL, Toledo RA, Montenegro FL, Correa-
Deur JE, Toledo SP. Early-onset, progressive, frequent, extensive, and
severe bone´ mineral and renal complications in multiple endocrine
neoplasia type 1-associated primary hyperparathyrodism. J Bone Miner
Res. 2010;25(11):2382-91, http://dx.doi.org/10.1002/jbmr.125.
Inherited endocrine tumors
Toledo SP et al.
CLINICS 2013;68(7):1039-1056
1052
46. Modigliani E, Coben R, Campos JM, Conte-Devolx B, Maes B, Boneu A,
et al. Prognostic factors for survival and for biochemical cure in
medullary thyroid carcinoma: results in 899 patients. The GETC Study
Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol
(Oxf). 1998;48(3):265-73, http://dx.doi.org/10.1046/j.1365-2265.1998.
00392.x.
47. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C,
et al. Early presentation of metastatic medullary cancer on multiple
endocrine neoplasia, type IIA: implications for therapy. J Pediatr.
1996;129(3):459-64, http://dx.doi.org/10.1016/S0022-3476(96)70084-7.
48. de Groot JWB, Links TP, Plukker JTM, Lips CJM, Hofstra RMW. RET as
a diagnostic and therapeutic target in sporadic and hereditary
endocrine tumors. Endocr Rev. 2006;27(5):535-60, http://dx.doi.org/
10.1210/er.2006-0017.
49. Montenegro FL, Lourenc¸o DM Jr, Tavares MR, Arap SS, Nascimento CP
Jr, Massoni Neto LM, et al. Total parathyroidectomy in a large cohort of
cases with hyperparathyroidism associated with multiple endocrine
neoplasia type 1: experience from a single academic center. Clinics.
2012;67 Suppl 1:131-9, http://dx.doi.org/10.6061/clinics/2012(Sup01)
22.
50. Coutinho FL, Lourenc¸o DM Jr, Toledo RA, Montenegro FL, Correia-
Deur JE, Toledo SP. Bone mineral density analysis in patients with
primary hyperparathyroidism associated with multiple endocrine
neoplasia type 1 after total parathyroidectomy. Clin Endocrinol (Oxf).
2010;72(4):462-8, http://dx.doi.org/10.1111/j.1365-2265.2009.03672.x.
51. Coutinho FL, Lourenco DM Jr, Toledo RA, Montenegro FL, Toledo SP.
Post-surgical follow-up of primary hyperparathyroidism associated
with multiple endocrine neoplasia type 1. Clinics. 2012;67 Suppl 1:169-
72, http://dx.doi.org/10.6061/clinics/2012(Sup01)28.
52. Giusti F, Tonelli F, Brandi ML. Primary hyperparathyroidism in
multiple endocrine neoplasia type 1: when to perform surgery?
Clinics. 2012;67 Suppl 1:141-4, http://dx.doi.org/10.6061/clinics/
2012(Sup01)23.
53. Melmed S. Acromegaly. N Engl J Med. 2006;355(24):2558-73.
54. Pellegata NS. MENX and MEN4. Clinics. 2012;67 Suppl 1:13-18, http://
dx.doi.org/10.6061/clinics/2012(Sup01)04.
55. Toledo RA, Sekiya T, Horvath A, Faucz F, Fragoso MC, Longuini VC,
et al. Assessing the emerging oncogene protein kinase C epsilon as a
candidate gene in families with Carney complex-2. Clin Endocrinol (Oxf).
2012;76(1):147-8, http://dx.doi.org/10.1111/j.1365-2265.2011.04144.x.
56. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M,
et al. Clinical predictors and algorithm for the genetic diagnosis of
pheochromocytoma patients. Clin Cancer Res. 2009;15(20):6378-85,
http://dx.doi.org/10.1158/1078-0432.CCR-09-1237.
57. Tonelli F, Giudici F, Cavalli T, Brandi ML. Surgical approach in patients
with hyperparathyroidism in multiple endocrine neoplasia type 1: total
versus partial parathyroidectomy. Clinics. 2012;67 Suppl 1:155-60,
http://dx.doi.org/10.6061/clinics/2012(Sup01)26.
58. Falchetti A, Brandi ML. Multiple endocrine neoplasia type I variants
and phenocopies: more than a nosological issue? J Clin Endocrinol
Metab. 2009;94(5):1518-20, http://dx.doi.org/10.1210/jc.2009-0494.
59. Nunes AB, Ezabella MC, Pereira AC, Krieger JE, Toledo SP. A novel
Val648Ile substitution in RET protooncogene observed in a Cys634Arg
multiple endocrine neoplasia type 2A kindred presenting with an
adrenocorticotropin-producing pheochromocytoma. J Clin Endocrinol
Metab. 2002;87(12):5658-61, http://dx.doi.org/10.1210/jc.2002-020345.
60. Peltonen L, Palotie A, Lange K. Use of population isolates for mapping
complex traits. Nat Rev Genet. 2000;1(3):182-90, http://dx.doi.org/10.
1038/35042049.
61. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, et al.
International RET Exon 10 Consortium. Risk profiles and penetrance
estimations in multiple endocrine neoplasia type 2A caused by
germline RET mutations located in exon 10. Hum Mutat.
2011;32(1):51-8, http://dx.doi.org/10.1002/humu.21385.
62. Machens A, Dralle H. Prophylactic thyroidectomy in RET carriers at
risk for hereditary medullary thyroid cancer. Thyroid. 2009;19(6):551-4,
http://dx.doi.org/10.1089/thy.2009.0144.
63. Pinto EM, Billerbeck AE, Villares MC, Domenice S, Mendonc¸a BB,
Latronico AC. Founder effect for the highly prevalent R337H mutation
of tumor suppressor p53 in Brazilian patients with adrenocortical
tumors. Arq Bras Endocrinol Metabol. 2004;48(5):647-50.
64. Schiavi F, Dematte` S, Cecchini ME, Taschin E, Bobisse S, Del Piano A,
et al. The endemic paraganglioma syndrome type 1: origin, spread, and
clinical expression. J Clin Endocrinol Metab. 2012;97(4):E637-41.
65. Chahal HS, Stals K, Unterlander M, Balding DJ, Thomas MG, Kumar
AV, et al. AIP mutation in pituitary adenomas in the 18th century and
today. New Eng. J. Med. 2011;364(1):43-50, http://dx.doi.org/10.1056/
NEJMoa1008020.
66. Knudson AG Jr, 1971. Mutation and cancer: statistical study of
retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820-3, http://dx.
doi.org/10.1073/pnas.68.4.820.
67. Koch CA, Pack K, Chrousos GP. The molecular pathogenesis of
hereditary and sporadic adrenocortical and adrenomedullary tumors.
J Clin Endocrinol Metab. 2002;87(12):5367-84, http://dx.doi.org/10.
1210/jc.2002-021069.
68. Lips CJ, Landsvater RM, Ho¨ppener JW, Geerdink RA, Blijham G, van
Veen JM, et al. Clinical screening as compared with DNA analysis in
families with multiple endocrine neoplasia type 2A. N Engl J Med.
1994;331(13):828-35.
69. Sanso GE, Domene HM, Garcia R, Pusiol E, Roque M, Ring A, et al.
Very early detection of RET proto-oncogene mutation is crucial for
preventive thyroidectomy in multiple endocrine neoplasia type 2
children: presence of C-cell malignant disease in asymptomatic carriers.
Cancer. 2002;94(2):323-30, http://dx.doi.org/10.1002/cncr.10228.
70. Pun˜ales MK, da Rocha AP, Meotti C, Gross JL, Maia AL. Clinical and
oncological features of children and young adults with multiple
endocrine neoplasia type 2A. Thyroid. 2008;18(12):1261-8, http://dx.
doi.org/10.1089/thy.2007.0414.
71. Diaz RE, Wohllk N. Multiple endocrine neoplasia; the Chilean
experience. Clinics. 2012;67 Suppl 1:7-11, http://dx.doi.org/10.6061/
clinics/2012(Sup01)03.
72. Pieterman CR, Schreinemakers JM, Koppeschaar HP, Vriens MR,
Rinkes IH, Zonnenberg BA et al. Multiple endocrine neoplasia type 1
(MEN1): its manifestations and effect of genetic screening on clinical
outcome. Clin Endocrinol (Oxf). 2009;70(4):575-81, http://dx.doi.org/
10.1111/j.1365-2265.2008.03324.x.
73. Lips CJ, Ho¨ppener JW, Van Nesselrooij BP, Van der Luijt RB.
Counselling in multiple endocrine neoplasia syndromes: from indivi-
dual experience to general guidelines. J Intern Med. 2005;257(1):69-77,
http://dx.doi.org/10.1111/j.1365-2796.2004.01429.x.
74. Gopie JP, Vasen HF, Tibben A. Surveillance for hereditary cancer: Does
the benefit outweigh the psychological burden? -A systematic
review.Crit Rev Oncol Hematol. 2012;83(3):329-40, http://dx.doi.org/
10.1016/j.critrevonc.2012.01.004.
75. Erlic Z, Hoffmann MM, Sullivan M, Franke G, Peczkowska M, Harsch I,
et al. Pathogenicity of DNA variants and double mutations in multiple
endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin
Endocrinol Metab. 2010;95(1):308-13, http://dx.doi.org/10.1210/jc.
2009-1728.
76. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in
a 4- to 20-year-old population. Ann N Y Acad Sci. 2006;1073(8):30-7.
77. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic
endocrine tumor syndromes: advances in molecular pathogenesis,
diagnosis, management, and controversies. Cancer. 2008;113(7
Suppl):1807-43, http://dx.doi.org/10.1002/cncr.23648.
78. Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, Gla¨sker S,
et al. Head and neck paragangliomas: clinical and molecular genetic
classification. Clinics. 2012;67 Suppl 1:19-28, http://dx.doi.org/10.
6061/clinics/2012(Sup01)05.
79. von Du¨cker L, Walz MK, Voss C, Arnold G, Eng C, Neumann HP.
Laparoscopic organ-sparing resection of von Hippel-Lindau disease-
associated pancreatic neuroendocrine tumors. World J Surg. 2011;35
(3):563-7, http://dx.doi.org/10.1007/s00268-010-0878-5.
80. Asher KP, Gupta GN, Boris RS, Pinto PA, Linehan WM, Bratslavsky G.
Robot-assisted laparoscopic partial adrenalectomy for pheochromocy-
toma: the National Cancer Institute technique, Eur Urol. 2011;60(1):118-
24, http://dx.doi.org/10.1016/j.eururo.2011.03.046.
81. Weisbrod AB, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK,
Linehan WM, et al. Association of type O blood with pancreatic
neuroendocrine tumors in Von Hippel-Lindau syndrome. Ann Surg
Oncol. 2012;19(6):2054-9, http://dx.doi.org/10.1245/s10434-012-2276-8.
82. Mannelli M, Lenders JW, Pacak K, Parenti G, Eisenhofer G. Subclinical
phaeochromocytoma. Best Pract Res Clin Endocrinol Metab.
2012;26(4):507-15, http://dx.doi.org/10.1016/j.beem.2011.10.008.
83. Ali T, Kandil D, Piperdi B. Long-term disease control with sunitinib in a
patient with metastatic pancreatic neuroendocrine tumor (NET)
associated with Von Hippel-Lindau syndrome (VHL). Pancreas.
2012;41(3):492-3, http://dx.doi.org/10.1097/MPA.0b013e31822a645e.
84. Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M, Kastner DL,
et al. Carney complex, a familial multiple neoplasia and lentiginosis
syndrome. Analysis of 11 kindreds and linkage to the short arm of
chromosome 2. J Clin Invest. 1996;97(3):699-705, http://dx.doi.org/10.
1172/JCI118467.
85. Vezzosi D, Bertherat J, Groussin L. Pathogenesis of benign adrenocor-
tical tumors. Best Pract Res Clin Endocrinol Metab. 2010;24(6):893-905,
http://dx.doi.org/10.1016/j.beem.2010.10.005.
86. Carney JA, Stratakis CA. Virilizing ovarian stromal tumor in a young
woman with Carney complex. Am J Surg Pathol. 2011;35(10):1592-1599.
87. Nozie`res C, Berlier P, Dupuis C, Raynaud-Ravni C, Morel Y, Chazot FB,
et al. Sporadic and genetic forms of paediatric somatotropinoma: a
retrospective analysis of seven cases and a review of the literature.
Orphanet J Rare Dis. 2011;24;6:67, http://dx.doi.org/10.1186/1750-
1172-6-67.
88. Anselmo J, Medeiros S, Carneiro V, Greene E, Levy I, Nesterova M, et al.
A large family with Carney complex caused by the S147G PRKAR1A
mutation shows a unique spectrum of disease including adrenocortical
CLINICS 2013;68(7):1039-1056 Inherited endocrine tumors
Toledo SP et al.
1053
cancer. J Clin Endocrinol Metab. 2012;97(2):351-359, http://dx.doi.org/
10.1210/jc.2011-2244.
89. Morin E, Mete O, Wasserman J, Joshua AM, Asa SL. Carney complex
with adrenal cortical carcinoma. J Clin Endocrinol Metab. 2012;97(2):
E202-206, http://dx.doi.org/10.1210/jc.2011-2321.
90. Bertherat J. Adrenocortical cancer in Carney complex: a paradigm of
endocrine tumor progression or an association of genetic predisposition
factors ? J Clin Endocrinol Metab. Metab. 2012;97(2):387-390, http://dx.
doi.org/10.1210/jc.2011-3327.
91. Briassoulis G, Kuburovic V, Xekouki P, Patronas N, Keil MF, Lyssikatos
C, Stajevic M, Kovacevic G, Stratakis CA. Recurrent left atrial myxomas
in Carney complex: a genetic cause of multiple strokes that can be
prevented. J Stroke Cerebrovasc Dis. 2012;21(8):914.e1-8, http://dx.doi.
org/10.1016/j.jstrokecerebrovasdis.2012.01.006.
92. Welander J, So¨derkvist P, Gimm O. Genetics and clinical characteristics
of hereditary pheochromocytomas and paragangliomas. Endocr Relat
Cancer. 2011;18(6):R253-276, http://dx.doi.org/10.1530/ERC-11-0170.
93. Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type
1, tuberous sclerosis and related syndromes. Best Pract Res Clin
Endocrinol Metab. 2010;24(3):439-449, http://dx.doi.org/10.1016/j.
beem.2010.02.002.
94. Uhlmann EJ, Plotkin SR. Neurofibromatoses. Adv Exp Med Biol.
2012;724:266-77, http://dx.doi.org/10.1007/978-1-4614-0653-2_20.
95. Stumpf DA, Alksne JF, Annegers JF,Neurofibromatosis. Conference
statement. National Institutes of Health Consensus Development
Conference. Arch Neurol. 1988;45(5):575-578.
96. Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo
M, et al. Generalized metabolic bone disease in Neurofibromatosis type
I. Mol Genet Metab. 2008;94(1):105-111, http://dx.doi.org/10.1016/j.
ymgme.2007.12.004.
97. Wang W, Nyman JS, Ono K, Stevenson DA, Yang X, Elefteriou F. Mice
lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia
similar to patients with neurofibromatosis type I. Hum Mol Genet.
2011;20(20):3910-3924, http://dx.doi.org/10.1093/hmg/ddr310.
98. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex
consensus conference: revised clinical diagnostic criteria. J Child Neurol.
1998;13(12):624-628, http://dx.doi.org/10.1177/088307389801301206.
99. Arva NC, Pappas JG, Bhatla T, Raetz EA, Macari M, Ginsburg HB, et al.
Well-differentiated pancreatic neuroendocrine carcinoma in tuberous
sclerosis--case report and review of the literature. Am J Surg Pathol.
2012;36(1):149-153, http://dx.doi.org/10.1097/PAS.0b013e31823d0560.
100. Ehninger D. From genes to cognition in tuberous sclerosis: implications
for mTOR inhibitotr-based treatment approaches. Neuropharmacol.
2013;68(5):97-105, http://dx.doi.org/10.1016/j.neuropharm.2012.05.
015.
101. Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2(4):475-484,
http://dx.doi.org/10.1177/1947601911413466.
102. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53
germline mutation carriers: a review of the IARC TP53 database.
Cancer. 2012;118(5):1387-1396, http://dx.doi.org/10.1002/cncr.26390.
103. Else T. Association of adrenocortical carcinoma with familial cancer
susceptibility syndromes. Mol Cell Endocrinol. 2012;351(1):66-70,
http://dx.doi.org/10.1016/j.mce.2011.12.008.
104. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E,
Lafferty AR et al. An inherited p53 mutation that contributes in a tissue-
specific manner to pediatric adrenal cortical carcinoma. Proc Natl
Acad Sci USA. 2001;98(16):9330-9335., http://dx.doi.org/10.1073/pnas.
161479898.
105. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini
MC, et al. An inherited mutation outside the highly conserved DNA-
binding domain of the p53 tumor suppressor protein in children and
adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab.
2001;86(10):4970-4973, http://dx.doi.org/10.1210/jc.86.10.4970.
106. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le
Calvez-Kelm F, et al. Detailed haplotype analysis at the TP53 locus in
p.R337H mutation carriers in the population of Southern Brazil:
evidence for a founder effect. Hum Mutat. 2010;31(2):143-150, http://
dx.doi.org/10.1002/humu.21151.
107. Pinto EM, Ribeiro RC, Kletter GB, Lawrence JP, Jenkins JJ, Wang J, et al.
Inherited germline TP53 mutation encodes a protein with an aberrant C-
terminal motif in a case of pediatric adrenocortical tumor. Fam Cancer.
2011;10(1):141-146, http://dx.doi.org/10.1007/s10689-010-9392-z.
108. Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The
International Pediatric Adrenocortical Tumor Registry initiative: con-
tributions to clinical, biological, and treatment advances in pediatric
adrenocortical tumors. Mol Cell Endocrinol. 2012;351(1):37-43, http://
dx.doi.org/10.1016/j.mce.2011.10.015.
109. Eng C. Will the real Cowden syndrome please stand up: revised
diagnostic criteria. J Med Genet. 2000;37(11):828-830, http://dx.doi.
org/10.1136/jmg.37.11.828.
110. Son EJ, Nose´ V. Familial follicular cell-derived thyroid carcinoma. Front
Endocrinol (Lausanne). 2012;3:61. doi: 10.3389.
111. Wohllk N, Schweizer H, Eric Z, Schmid KW, Walz MK, Raue F, et al.
Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol
Metab. 2010;24(3):371-387, http://dx.doi.org/10.1016/j.beem.2010.02.
001.
112. Raue F, Frank-Raue K. Genotype-phenotype correlation in multiple
endocrine neoplasia type 2. Clinics. 2012;67 Suppl 1:69-75, http://dx.
doi.org/10.6061/clinics/2012(Sup01)13.
113. Wagner SM, Zhu S, Nicolescu AC, Mulligan LM. Molecular mechan-
isms of RET receptor-mediated oncogenesis in multiple endocrine
neoplasia 2. Clinics. 2012;67 Suppl 1:77-84, http://dx.doi.org/10.6061/
clinics/2012(Sup01)14.
114. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS
mutations in RET-negative sporadic medullary thyroid carcinomas.
J Clin Endocrinol Metab. 2011;96(5):E863-868, http://dx.doi.org/10.
1210/jc.2010-1921.
115. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al.
Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant
and Mutually Exclusive Oncogenic Mutations in RET and RAS. J Clin
Endocrinol Metab. 2013;98(2):E364-369, http://dx.doi.org/10.1210/jc.
2012-2703.
116. Qi XP, Ma JM, Du ZF, Ying RB, Fei J, Jin HY, et al. RET germline
mutations identified by exome sequencing in a Chinese multiple
endocrine neoplasia type 2A/familial medullary thyroid carcinoma
family. PLoS One. 2011;6(5):e20353, http://dx.doi.org/10.1371/journal.
pone.0020353.
117. Conzo G, Circelli L, Pasquali D, Sinisi A, Sabatino L, et al. Lessons to be
learned from clinical management of a MEN2A patient bearing a novel
634/640/700 mutation of the RET prto-oncogene. Clin Endocrinol. Clin
Endocrinol 2012;77(6):934-936, http://dx.doi.org/10.1111/j.1365-2265.
2012.04412.x.
118. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al.
Prognostic significance of somatic RET oncogene mutations in sporadic
medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol
Metab. . 2008;93(3):682-687.
119. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M,
et al. A new hot spot for mutations in the ret protooncogene causing
familial medullary thyroid carcinoma and multiple endocrine neoplasia
type 2A. J Clin Endocrinol Metab. 1998;83(3):770-774, http://dx.doi.
org/10.1210/jc.83.3.770.
120. Cosci B, Vivaldi A, Romei C, Genignani F, Landi S, Ciampi R, et al. In
silico and in vitro analysis of rare germline allelic variants of RET
oncogene associated with mrdullary thyroid carcinoma. Endocr Relat
Cancer. 2011;18(5):603-612, http://dx.doi.org/10.1530/ERC-11-0117.
121. Machens A, Frank-Raue K, Lorenz K, Rondot S, Raue F, Dralle H.
Clinical relevance of RET variants G691S, L769L, S836S and S904S to
sporadic medullary thyroid cancer. Clin Endocrinol (Oxf). 2012;76
(5):691-697 , http://dx.doi.org/10.1111/j.1365-2265.2011.04293.x.
122. Ceolin L, Siqueira DR, Ferreira CV, Romitti M, Maia SC, Leiria L, et al.
Additive effect of RET polymorphisms on sporadic medullary thyroid
carcinoma susceptibility and tumor aggressiveness. Eur J Endocrinol.
2012;166(5):847-854.
123. Lendvai N, To´th M, Valkusz Z, Beko˝ G, Szu¨cs N, Csajbo´k E, et al. Over-
representation of the G12S polymorphism of the SDHD gene in patients
with MEN2A syndrome. Clinics. 2012;67 Suppl 1:85-89, http://dx.doi.
org/10.6061/clinics/2012(Sup01)15.
124. Menko FH, van der Luijt RB, de Valk IA, Toorians AW, Sepers JM, van
Diest PJ, et al. Atypical MEN type 2B associated with two germline RET
mutations on the same allele not involving codon 918. J Clin Endocrinol
Metab. Metab. 2002;87(1):393-397, http://dx.doi.org/10.1210/jc.87.1.
393.
125. Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, et al.
Identification of a novel point mutation in the RET gene (Ala883Thr),
which is associated with medullary thyroid carcinoma phenotype only
in homozygous condition. J Clin Endocrinol Metab. 2004;89(11):5823-
5827, http://dx.doi.org/10.1210/jc.2004-0312.
126. Mukherjee S, Zakalik D. RET codon 804 mutations in multiple
endocrine neoplasia 2: genotype-phenotype correlations and implica-
tions in clinical management. Clin Genet. 2011;79 (1):1-16, http://dx.
doi.org/10.1111/j.1399-0004.2010.01453.x.
127. Lindsey SC, Kunii IS, Germano-Neto F, Sittoni MY, Camacho CP,
Valente FO, et al. Extended RET Gene Analysis in Patients with
Apparently Sporadic Medullary Thyroid Cancer: Clinical Benefits and
Cost. Horm Cancer. 2012;3(4):181-186, http://dx.doi.org/10.1007/
s12672-012-0109-7.
128. Moore SW, Zaahl M. The Hirschsprung’s-multiple endocrine neoplasia
connection. Clinics. 2012;67 Suppl 1:63-67, http://dx.doi.org/10.6061/
clinics/2012(Sup01)12.
129. Quedas EP, Longuini VC, Sekiya T, Coutinho FL, Toledo SP, Tannuri U,
et al. RET haplotype, not linked to the C620R activating mutation,
associated with Hirschsprung disease in a novel MEN2 family. Clinics.
2012;67 Suppl 1:57-61, http://dx.doi.org/10.6061/clinics/2012(Sup01)
11.
130. Hyndman BD, Gujral TS, Krieger JR, Cockburn JG, Mulligan LM.
Multiple functional effects of RET kinase domain sequence variants in
Hirschsprung disease. Hum Mutat. 2013;34 (1): 132-142, http://dx.doi.
org/10.1002/humu.22170.
Inherited endocrine tumors
Toledo SP et al.
CLINICS 2013;68(7):1039-1056
1054
131. Mian C, Sartorato P, Barollo S, Zane M, Opocher G. RET codon
609 mutations: a contribution for better clinical managing. Clinics.
2012;67 Suppl 1:33-36, http://dx.doi.org/10.6061/clinics/2012(Sup01)
07.
132. Vasen HF, Nieuwenhuijzen Kruseman AC, Moers AM, Lips CJ, Beukers
EK, et al. MEN-2 syndrome: the value of screening and central
registration; a study of six kindreds in The Netherlands. Am J Med.
1987;35 (2-3):101-103.
133. Lips CJ, Landsvater RM, Ho¨ppener JW, Geerdink RA, Blijham G, van
Veen JM, et al. Clinical screening as compared with DNA analysis in
families with multiple endocrine neoplasia type 2A. N Engl J Med.
1994;331(13):828-835.
134. Ezabella MC, Hayashida CY, Bisi H, Leite MO, Borelli A, Abelin NM,
et al. Early detection of medullary thyroid carcinoma in multiple
endocrine neoplasia type II. Rev Hosp Clin Fac Med Sao Paulo.
1990;45(3):105-109.
135. Machens A, Dralle H. Simultaneous medullary and papillary thyroid
cancer: a novel entity? Ann Surg Oncol. 2012;19(1):37-44, http://dx.doi.
org/10.1245/s10434-011-1795-z
136. Toledo SP, Lourenc¸o DM Jr, Santos MA, Tavares MR, Toledo RA,
Correia-Deur JE. Hypercalcitoninemia is not pathognomonic of medul-
lary thyroid carcinoma. Clinics. 2009;64(7):699-706.
137. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S,
et al. Predictive value of serum calcitonin levels for preoperative
diagnosis of medullary thyroid carcinoma in a cohort of 5817
consecutive patients with thyroid nodules. J Clin Endocrinol Metab.
2007;92(2):450-455.
138. Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, et al.
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from
the ItaMEN network analysis on the prevalence of different genotypes
and phenotypes. Eur J Endocrinol. 2010;163(2):301-308.
139. Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB,
Cerutti JM. A novel germ-line point mutation in RET exon 8
(Gly(533)Cys) in a large kindred with familial medullary thyroid
carcinoma. J Clin Endocrinol Metab. 2003;88(11):5438-5443, http://dx.
doi.org/10.1210/jc.2003-030997.
140. Muzza M, Cordella D, Bombled J, Bressac-de Paillerets B, Guizzardi F,
Francis Z, et al. Four novel RET germline variants in exons 8 and 11
display an oncogenic potential in vitro. Eur J Endocrinol. 2010;162(4):771-
777.
141. Hisano M, Vicentini FC, Srougi M. Retroperitoneoscopic adrenalectomy
in pheochromocytoma. Clinics. 2012;67 Suppl 1:161-167, http://dx.doi.
org/10.6061/clinics/2012(Sup01)27.
142. Schlumberger M, Massicotte MH, Nascimento CL, Chougnet C, Baudin
E, Leboulleux S. Kinase inhibitors for advanced medullary thyroid
carcinoma. Clinics. 2012;67 Suppl 1:125-129, http://dx.doi.org/10.
6061/clinics/2012(Sup01)21.
143. Lips CJ, Dreijerink KM, Hoppener JW. Variable clinical expression in
patients with a germline MEN1 disease gene mutation: clues to a
genetype-phenotype correlation. Clinics. 2012;67 Suppl 1:49-56, http://
dx.doi.org/10.6061/clinics/2012(Sup01)10.
144. Lairmore TC, Piersall LD, DeBenedetti MK, Dilley WG, Mutch MG,
Whelan AJ, et al. Clinical genetic testing and early surgical intervention
in patients with multiple endocrine neoplasia type 1 (MEN 1). 2004;239
(5):637-645.
145. Machens A, Schaaf L, Karges W. Age-related penetrance of endocrine
tumors in multiple endocrine neoplasia type 1(MEN1): a multicentre
study of 258 gene carriers. Clin Endocrinol 2007;67(4):613-622.
146. Syro LV, Scheithauer BW, Kovacs K, Toledo RA, London˜o FJ, Ortiz LD,
et al. Pituitary tumors in patients with MEN1 syndrome. Clinics.
2012;67 Suppl 1:43-48, http://dx.doi.org/10.6061/clinics/2012(Sup01)
09.
147. de Herder WW. Familial gigantism. Clinics. 2012;67 suppl 1: 29-32,
http://dx.doi.org/10.6061/clinics/2012(Sup01)06
148. Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, et al.
Temozolomide in aggressive pituitary adenomas and carcinomas.
Clinics. 2012;67 Suppl 1:119-123, http://dx.doi.org/10.6061/clinics/
2012(Sup01)20.
149. Farrell WE, Azevedo MF, Batista DL, Smith A, Bourdeau I, Horvath A,
et al. Unique gene expression profile associated with an early-onset
multiple endocrine neoplasia (MEN1)-associated pituitary adenoma.
J Clin Endocrinol Metab. 2011;96 (11): E1905-914 , http://dx.doi.org/10.
1210/jc.2011-1127.
150. Simonds WF, Varghese S, Marx SJ, Nieman LK. Cushing’s syndrome in
multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2012;76
(3):379-386, http://dx.doi.org/10.1111/j.1365-2265.2011.04220.x.
151. Agarwal SK, Ozawa A, Mateo CM, Marx SJ. The MEN1 gene and
pituitary tumours. Horm Res. 2009;71 Suppl 2:131-138, http://dx.doi.
org/10.1159/000192450.
152. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK,
et al. Prospective study of surgery for primary hyperparathyroidism
(HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison
syndrome: long-term outcome of a more virulent form of HPT. Ann Surg.
2008;247(3):501-510, http://dx.doi.org/10.1097/SLA.0b013e31815efda5.
153. Skogseid B, Rastad J, A˚kerstro¨m G. Pancreatic endocrine tumors in
multiple endocrine neoplasia type I. Doherty GM, Skogseid B, editors.
Surgical Endocrinology Philadelphia, PA: Lippincott, Williams &
Wilkins; 2001. pp. 511-524.
154. A˚kerstro¨m G, Sta˚lberg P. Surgical management of MEN-1 and -2: State
of the art. Surg Clin N Am. 2009;89(5):1047-1068.
155. Triponez F, Goudet P, Dosseh D, Cougard P, Bauters C, Murat A, et al.
Is surgery beneficial for MEN1 patients with small (,or = 2 cm),
nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of
65 patients from the GTE. World J Surg. 2006;30(5):654-662 .
156. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, et al.
Epidemiology data on 108 MEN 1 patients from the GTE with isolated
nonfunctioning tumors of the pancreas. Ann Surg. 2006;243(2):265-272,
http://dx.doi.org/10.1097/01.sla.0000197715.96762.68.
157. Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski
P, et al. Risk factors and causes of death in MEN1 disease. A GTE
(Groupe d’Etude des Tumeurs Endocrines) cohort study among 758
patients. World J Surg. 2010;34(2):249-255 .
158. Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN-1 gene
in a large kindred with multiple endocrine neoplasia type 1. J Intern
Med. 1998;243(6):465-470, http://dx.doi.org/10.1046/j.1365-2796.1998.
00275.x.
159. Burgess JR, David R, Parameswaran V, Greenaway TM, Shepherd JJ.
The outcome of subtotal parathyroidectomy for the treatment of
hyperparathyroidism in multiple endocrine neoplasia type 1. Arch
Surg. 1998;133(2):126-129, http://dx.doi.org/10.1001/archsurg.133.2.
126.
160. Wells SA Jr, Stirman JA Jr, Bolman RM 3rd, Gunnells JC.
Transplantation of the parathyroid glands. Clinical and experimental
results. Surg Clin North Am. 1978;58(2):391-402..
161. Scholten A, Schreinemakers JM, Pieterman CR, Valk GD, Vriens MR,
Borel Rinkes IH. Evolution of surgical treatment of primary hyperpar-
athyroidism in patients with multiple endocrine neoplasia type 2A.
Endocr Pract. . 2011;17(1):7-15, http://dx.doi.org/10.4158/EP10050.OR.
162. Cohen MS, Dilley WG, Wells SA Jr, Moley JF, Doherty GM, Sicard GA,
et al. Long-term functionality of cryopreserved parathyroid autografts:
a 13-year prospective analysis. Surgery. 2005;138(6):1033-1034, http://
dx.doi.org/10.1016/j.surg.2005.09.029.
163. Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, Kleerekoper M, Neer R,
Peacock M, et al. Summary statement from a workshop on asympto-
matic primary hyperparathyroidism: a perspective for the 21st century.
J Clin Endocrinol Metab. 2002;87(12):5353-5361, http://dx.doi.org/10.
1210/jc.2002-021370.
164. Brandi ML. Parathyroid gland: Hyperparathyroidism in MEN1 syn-
drome: time to operate? Nat Rev Endocrinol. 2010;6(11):604--605,
http://dx.doi.org/10.1038/nrendo.2010.131.
165. Burgess JR, David RB, Greenaway TM, Parameswaran V, Shepherd JJ.
Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical
significance, relationship to primary hyperparathyroidism and
response to parathyroidectomy. Arch Surg. 1999;134(10):1119-1123,
http://dx.doi.org/10.1001/archsurg.134.10.1119.
166. Costa MH, Domenice S, Toledo RA, Lourenc¸o DM Jr, Latronico AC,
Pinto EM, et al. Glucose-dependent insulinotropic peptide receptor
overexpression in adrenocortical hyperplasia in MEN1 syndrome
without loss of heterozygosity at the 11q13 locus. Clinics. 2011;66
(4):529-533.
167. Lewis MA, Thompson GB, Young WF Jr. Preoperative assessment of the
pancreas in multiple endocrine neoplasia type 1.World J Surg. Surg.
2012;36(6):1375-8131.
168. Zhang L, Smyrk TC, Young WF Jr, Stratakis CA, Carney JA. Gastric
stromal tumors in Carney triad are different clinically, pathologically,
and behaviorally from sporadic gastric gastrointestinal stromal tumors:
findings in 104 cases. Am J Surg Pathol. 2010;34(1):53-64.
169. Lips CJ, Lentjes EG, Ho¨ppener JW. The spectrum of carcinoid tumours
and carcinoid syndromes. Ann Clin Biochem. 2003;40(Pt 6):612-627,
http://dx.doi.org/10.1258/000456303770367207.
170. Ferolla P, Falchetti A, Filosso P, Tomassetti P, Tamburrano G, Avenia N,
Daddi G, Puma F, Ribacchi R, Santeusanio F, Angeletti G, Brandi ML.
Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine
neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab.
2005;90(5):2603-2609, http://dx.doi.org/10.1210/jc.2004-1155.
171. Burgess JR, Giles N, Shepherd JJ. Malignant thymic carcinoid is not
prevented by transcervical thymectomy in multiple endocrine neoplasia
type 1. Clin Endocrinol (Oxf). 2001;55 (5):689-693, http://dx.doi.org/10.
1046/j.1365-2265.2001.01348.x.
172. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T,
et al. Germline cdkn1b/p27kip1 mutation in multiple endocrine
neoplasia. J Clin Endocrinol Metab. 2007;92(8):3321-3325, http://dx.
doi.org/10.1210/jc.2006-2843.
173. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-
dependent kinase inhibitor genes in multiple endocrine neoplasia type
1 and related states. J Clin Endocrinol Metab. 2009;94(5):1826-1834,
http://dx.doi.org/10.1210/jc.2008-2083.
CLINICS 2013;68(7):1039-1056 Inherited endocrine tumors
Toledo SP et al.
1055
174. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirova MA, Beckers
B. High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in
the Province of Lie`ge, Belgium. J Clin Endocrinol Metab. 2006;9 1
(12):4769-4775, http://dx.doi.org/10.1210/jc.2006-1668.
175. De Herder WW. Acromegalic gigantism, physicians and body snatch-
ing. Past or present? Pituitary. 2012;15(3): 312-318, http://dx.doi.org/
10.1007/s11102-012-0389-5.
176. Jorge BH, Agarwal SK, Lando VS, Salvatori R, Barbero RR, Abelin N,
et al. Study of the multiple endocrine neoplasia type 1, growth
hormone-releasing hormone receptor, Gs alpha, and Gi2 alpha genes
in isolated familial acromegaly. J Clin Endocrinol Metab. 2001;86
(2):542-544, http://dx.doi.org/10.1210/jc.86.2.542.
177. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA,
Guitelman MA, et al. Aryl hydrocarbon receptor-interacting protein
gene mutations in familial isolated pituitary adenomas: analysis in 73
families. J Clin Endocrinol Metab. 2007;92(5):1891-1896, http://dx.doi.
org/10.1210/jc.2006-2513.
178. Rothenbuhler A, Stratakis CA. Clinical and molecular genetics of
Carney complex. Best Pract Res Clin Endocrinol Metab. 2010;24(3):389-
399, http://dx.doi.org/10.1016/j.beem.2010.03.003.
179. Syro LV, Sundsbak JL, Scheithauer BW, Toledo RA, Camargo M, Heyer
CM, et al. Somatotroph pituitary adenoma with acromegaly and
autosomal dominant polycystic kidney disease: SSTR5 polymorphism
and PKD1 mutation. Pituitary. 2012;15(3):342-349, http://dx.doi.org/
10.1007/s11102-011-0325-0.
180. Vasilev V, Daly A, Naves L, Zacharieva S, Beckers A. Clinical and
genetic aspects of familial isolated pituitary adenomas. Clinics. 2012;67
Suppl 1:37-41, http://dx.doi.org/10.6061/clinics/2012(Sup01)08.
181. Toledo RA, Mendonca BB, Fragoso MC, Soares IC, Almeida MQ, Moraes
MB, et al. Isolated familial somatotropinoma: 11q13-loh and gene/
protein expression analysis suggests a possible involvement of aip also in
non-pituitary tumorigenesis. Clinics. 2010;65(4):407-415, http://dx.doi.
org/10.1590/S1807-59322010000400010.
182. Toledo RA, Lourenc¸o DM Jr, Toledo SP. Familial isolated pituitary
adenoma: evidence for genetic heterogeneity. Front Horm Res. 2010;
38:77-86 , http://dx.doi.org/10.1159/000318497.
183. Jennings JE, Georgitsi M, Holdaway I, Daly AF, Tichomirowa M,
Beckers A, et al. Aggressive pituitary adenomas occurring in young
patients in a large Polynesian kindred with a germline R271W mutation
in the AIP gene. Eur J Endocrinol. 2009;161(5):799-804
184. Carney JA, Young WF, Stratakis CA. Primary bimorphic adrenocortical
disease: cause of hypercortisolism in McCune-Albright syndrome.
Am J Surg Pathol. 2011;35(9):1311-1326.
185. McDonald TJ, Driedger AA, Garcia BM, Van Uum SH, Rachinsky I,
Chevendra V et al. Familial papillary thyroid carcinoma: a retrospective
analysis. J Oncol. 2011;2011:948786.
186. Domingues R, Tomaz RA, Martins C, Nunes C, Bugalho MJ, Cavaco
BM. Identification of the first germline HRPT2 whole-gene deletion in a
patient with primary hyperparathyroidism. Clin Endocrinol (Oxf).
2012;76(1):33-38., http://dx.doi.org/10.1111/j.1365-2265.2011.04184.x.
187. Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G,
et al. Prevalence and Characteristics of Familial Hyperaldosteronism.
The PATOGEN Study (Primary Aldosteronism in TOrino-GENetic
forms). Hypertension. 2011;58(5):797-803, http://dx.doi.org/10.1161/
HYPERTENSIONAHA.111.175083.
188. Funder JW, Carey RM, Fardela C, Gomez-Sanchez C, Mantero F,
Stowasser M, et al. Case Detection, Diagnosis, and Treatment of Patients
with Primary Aldosteronism: An Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2008;93(9):3 266-281.
189. Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A,
et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau
disease tumour suppressor gene in sporadic and syndromic phaeo-
chromocytomas. J Clin Genet. 1995;32(12):934-937.
190. Qin Y, Buddavarapu K, Dahia PL. Pheochromocytomas: from genetic
diversity to new paradigms. Horm Metab Res. 2009;41(9):664-671,
http://dx.doi.org/10.1055/s-0029-1215590.
191. Dahia PL, Hao K, Rogus J, Colin C, Pujana MA, Ross K, et al. Novel
pheochromocytoma susceptibility loci identified by integrative geno-
mics. Cancer Res. 2005;65(21):9651-c-9658, http://dx.doi.org/10.1158/
0008-5472.CAN-05-1427.
192. Neumann HP, Sullivan M, Winter A, Malinoc A, Hoffmann MM,
Boedeker CC, et al. Germline mutations of the TMEM127 gene in
patients with paraganglioma of head and neck and extraadrenal
abdominal sites. J Clin Endocrinol Metab. 2011;96(8):E1279-282,
http://dx.doi.org/10.1210/jc.2011-0114.
193. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol.
2011;7(5):257-266, http://dx.doi.org/10.1038/nrendo.2011.40.
194. Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T, et al.
Multiple endocrine neoplasia type 1 (MEN1): not only inherited
endocrine tumors. Gen Med. 2009;11(12):825-835 , http://dx.doi.org/
10.1097/GIM.0b013e3181be5c97.
195. Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary
adenomas (FIPA) and pituitary adenoma predisposition due to
mutations in the aryl hydrocarbon receptor interacting protrin (AIP)
gene. Endocr Rev. 2013;34(2):239-277, http://dx.doi.org/10.1210/er.
2012-1013.
196. Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET
protooncogene: from bedside to bench to bedside. Mol Cell Endocrinol.
2006,9;247(1-2):34-40, http://dx.doi.org/10.1016/j.mce.2005.10.028.
197. Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF,
Vanbellinghen JF, et al. Expression of aryl hydrocarbon receptor (AHR)
and AHR-interacting protein in pituitary adenomas: pathological and
clinical implications. Endocr Relat Cancer. 2009;16(3):1029-1043, http://
dx.doi.org/10.1677/ERC-09-0094.
198. Romei C, Pardi E, Cetani F, Elisei R. Genetic and Clinical Features of
Multiple Endocrine Neoplasia Types 1 and 2. J Oncol. 2012;2012:705036.
Inherited endocrine tumors
Toledo SP et al.
CLINICS 2013;68(7):1039-1056
1056
